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Human mesenchymal stem cells (hMSCs) are a promising cell therapy candidate for 
the treatment of several clinical conditions. In recent years, the use of extracellular ves-
icles emerges for therapeutic purposes. Most of cells indeed release a wide range of 
extracellular vesicles of different size, content and functions, which interact with target 
cells by modifying the phenotype or function. 
Manufacture of hMSCs requires in vitro isolation and expansion to increase the avail-
able number of final products to meet clinical demand. Through Autostem (EU-H2020 
proposal) European academic and industrial group worked in collaboration to enable 
large-scale hMSCs production, at clinical-grade quality, by implementing a robotic auto-
mated pipeline for cell isolation and culture. The goal is to develop an automated, closed 
and good manufacturing practice (GMP) MSC cell technology, a “StromalCellFactory” to 
produce allogenic hBMSCs to use in therapy. 
We developed a “donor-to-patient” system for aseptic therapeutic cell manufacturing 
using a xeno-free medium. We characterized cells, secretome and extracellular vesicles 
of hBMSCs, isolated in plastic adherence and grown in FBS and in a chemically defined 
xeno-free medium, compared to hBMSCs isolated in a 3D-bioreactor, demonstrating that 
our serum-free system allow to select a highly proliferating-hBMSC population with a 
strong osteogenic potential, both in vitro and in vivo. These cells have also a secretion 
pattern characterized by biological factors involved in homeostasis, wound healing and 
angiogenesis, beside showing a stronger extracellular vesicles secretion.  
We validated also the potential therapeutic benefits of secreted factors, conditioned 
medium and exosomes isolated from hBMSCs cultured in our culture system, for carti-
lage repair. 
In a damaged tissue, the initial inflammatory response plays a key role triggering tissue 
repair and homeostasis, but can be detrimental in the long term, causing fibrosis. We 
observed that under inflammatory condition human Articular Chondrocytes (hACs) are 
able to internalize and recruit more MSC-derived exosomes, compare to the control 
chondrocytes. We investigated the effects of conditioned medium and extracellular ves-
icles in the activation of different regeneration pathways (IL6, IL8, COX2 and NF-kB).  
The effect of MSCs-derived conditioned media and exosomes revealed to be regener-
ating and protective for the articular cartilage and they may be a possible therapy for 
osteoarthritis. 
  





Regenerative medicine has been defined as the process of replacement or regenera-
tion of human cells, tissues or organs to restore or establish a normal function.1 
The term “regenerative medicine” was introduced by William Haseltine during a 1999 
conference on Lake Como, in the attempt to describe an emerging field, which blends 
knowledge deriving from different subjects: tissue engineering, cell transplantation, stem 
cell biology, biomechanics prosthetics, nanotechnology, biochemistry. Historically, this 
term was found for the first time in a 1992 paper by Leland Kaiser, who listed the tech-
nologies which would impact the future of hospitals.2  
The concept of regeneration is commonly observed, but often unappreciated in daily 
medical practice. The regeneration of body parts is a rather common phenomenon in 
nature, a salamander can regenerate an amputated limb in several days.3 Humans have 
this ability as well, but they lose it over the years: a severed fingertip can regenerate until 
11 years of age.4 Therefore, regenerative medicine uses, when possible, the body's self-
regenerative capacities. The normal maintenance of tissues in an adult organism is guar-
anteed by natural mechanisms of tissue regeneration. In humans, however, the regen-
erative capacities are often insufficient to face off serious pathological conditions, which 
lead to a progressive loss of tissue.  
The aim of regenerative medicine is to restore normal structure and function following 
tissue injury and it is defined by the convergent repair triad of replacement, regeneration, 
and rejuvenation (the R3 paradigm, Fig.1). These strategies overlap and conceptualize 
the scope of regenerative medicine, ranging from transplantation of used parts (“replace-
ment”) to development of new parts (“regeneration”) to induction of self‐renewed parts 
(“rejuvenation”).5 
 
Figure 1 The scope of regenerative medicine. Repair is the central goal of regenerative medicine that 
encompasses the general strategy triad: replacement, regeneration, and rejuvenation. Replacement is de-
fined as repair of damaged tissue by recycling used parts through tissue/organ transplantation. Regeneration 
is defined as repair of damaged tissue through differentiation of progenitor cells to replace damaged cells 
and restore tissue function. Rejuvenation is defined as repair of damaged tissue through activation of en-
dogenous resident stem cells that can stimulate biogenesis and replenish functional tissue. Collectively, 
therapeutic repair strategies are recognized as the “R3” regenerative medicine paradigm.5 




Replacement strategy refers to transplantation of a cell‐based product that re‐estab-
lishes homeostasis for the recipient through continuation of the tissue function from the 
donor.6 The transplantation is the replacement of an organ or a tissue with another taken 
from the same organism (homo-transplantation, better referred to as autologous trans-
plantation), from another organism of the same species (allo-transplantation) or from an 
individual of different species (xeno-transplantation7,8). There are different types of trans-
plant, also based on the implant site of the new organ: orthotopic (the original malfunc-
tioning organ is removed, and the organ of the donor is placed in the same anatomical 
position of the original organ), heterotopic (a new organ is flanked by the old one no 
longer functioning, but remains in its place as in cardiac surgery where the heart of the 
donor is sutured on the right side of the receiver's heart that remains in situ)9–11, or ectopic 
(a new organ, or more often a tissue, is taken from a certain anatomical area to be im-
planted in a different one, where it will be able to regenerate the recipient tissue or organ, 
as in the case of skin transplantation12–15).16–18 
Unfortunately, transplantation brings with it several problems and complications. The 
issues that arise are related to the disproportion between the demand and the effective 
availability of organs conforming to the donation, the risks of bacterial or viral infections 
and the necessary compatibility between the donor and recipient individual. Beyond that, 
after transplantation it is essential to follow a therapy with immunosuppressive drugs 
aimed at preventing the phenomenon of rejection. They cause a marked deterioration of 
the overall patient life condition, causing metabolic imbalances, cardiovascular disorders 
and greater susceptibility to bacterial and viral pathogens, due to a drastic decline of the 
body's immune defences.19–23 
This type of drawbacks could be largely avoided through the new regenerative medi-
cine approaches. Indeed, recent advances in this field have shown that it is possible to 
stimulate tissue repair mechanisms to improve endogenous tissue regeneration.24 
Regenerative medicine has the potential to heal or replace tissues and organs dam-
aged by age, disease or trauma.25 Preclinical and clinical data support the possibility of 
treating both chronic and acute diseases, including skin wounds, cardiovascular dis-
eases and treatment for some types of cancer, such as leukaemia.26 Since several dec-
ades ago, a wide number of regenerative medicine therapies, including orthopaedics and 
wound healing applications, have received the Food and Drug Administration (FDA) ap-
proval and they are now used in clinical settings.27 
The field of regenerative medicine includes numerous strategies, including gene ther-
apy, cell therapy and tissue engineering. The innate body repair mechanisms can be 
exploited to promote endogenous regeneration; indeed, the main objective of regenera-
tive medicine is to refine the methods of using the elements necessary to trigger in vivo 
self-regeneration.28 
The term "tissue engineering", defined in 1988 by members of the National Science 
Foundation (NSF), indicates a multidisciplinary field that applies the principles of biology 
and engineering, for the development of biological substitutes that restore, maintain or 
improve the tissue functionality.29 
The similarity between these two fields has allowed their merger into a single field of 
“tissue engineering and regenerative medicine (TERM)”. TERM makes use of cells 
(and/or their products), supports and molecular factors to develop bioactive tissue 
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substitutes. The cells are made to interact with three-dimensional biocompatible matri-
ces, consisting of biomaterials, whose chemical, mechanical and physical characteristics 
are suitably modulated. The construct thus formed is transplanted into the target organ, 
where the cells can establish cell-cell and cell-matrix contacts by receiving precise posi-
tional information. 
The basic elements on which tissue engineering is based are therefore: i) cells (differ-
entiated, progenitor and stem cells), ii) bioactive molecules (responsible for the estab-
lishment of the correct tissue microenvironment), iii) Three-dimensional supports (or ma-




Figure 2 Tissue engineering approaches with a combination of cells, biofactors and scaffolds. Patients 
derived stem cells, expanded ex vivo, are subsequently mixed with morphogens and placed in a 3D scaffold 
to initiate differentiation. The engineered scaffold will either undergo a period of ex vivo pre-implantation 




Stem Cell therapy: an overview 
Stem-cell therapy is the use of stem cells to treat or prevent a disease or clinical con-
dition. Bone marrow transplant is the most widely used stem-cell therapy, but some ther-
apies derived from umbilical cord blood are also in use. Research is underway to develop 
various sources for stem cells, as well as to apply stem-cell treatments for neurodegen-
erative diseases and conditions such as diabetes and heart disease, among others.32  
The two fundamental historical facts that made cell therapy formulated and feasible 
were the discovery of pluripotent stem cells of embryonic origin, awarded the Nobel Prize 
for Medicine in 2007 to Mario R. Capecchi, Martin J. Evans, and Oliver Smithies, and the 
identification of staminal niches, or tissue regions that host the cell population responsi-
ble for repairing the tissue in which they reside.33 
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When we talk about stem cells, it is essential to define several stem criteria: i) Self-
renewal capacity (the cell must be able to give rise to a more or less defined number of 
mitotic divisions with the aim of self-maintenance of the healthy and renewed stem pop-
ulation), ii) plasticity (the cells derived from the mitotic division must give rise to differen-
tiation in at least one other cell type besides the stem cell) iii) A stem cell population must 
be able to repopulate the tissue of origin if transplanted to a damaged recipient site, iv) 
stem cells placed in vivo in the absence of tissue damage must be able to contribute to 
the supply of a differentiating progeny.  
The self-renewal is at the basis of the homeostasis of a tissue and it is fundamental for 
the proper maintenance of the organ over time, as it allows to have a cellular pool capa-
ble of providing new cells, which replace the previous ones that have undergone physi-
ological aging. From a mitotic stem cell, it is possible to obtain two identical stem cells 
(symmetric division), or two identical cells aimed at a differentiation pathway or a stem 
cell identical to the mother cell and one that will undergo a differentiation process (asym-
metric division). The latter system of division therefore seems to be the main mechanism 
responsible for maintaining a stem cell pool, by generating a poorly proliferating daughter 
stem cell and a daughter cell in differentiation, able to give new mature terminally differ-
entiated cells, which will compose the tissue.34 
The second fundamental property of stem cells mentioned above, plasticity, is classi-
cally defined as the ability of stem cells to differentiate to cell types both typical of the 
stem-source district or strangers. In recent years, the possibility that stem cells could 
generate cell types belonging to tissues different from the one of origin opened new 
questions and perspectives.35 The research focused on those cells that have shown a 
greater susceptibility towards non-classical differentiation and therefore a higher plastic-
ity potential. They are Haematopoietic Stem Cells (HSCs), Neural Stem Cells (NSCs) 
and Mesenchymal Stem Cells (MSCs). Recently, experiments aimed to obtain alterna-
tive cell types are scrupulously evaluated, trying to avoid artefacts, possibly driven by 
too strong experimental conditions, not in vivo-reproducible. 
Stem cell is therefore an undifferentiated cell, which can self-renew to replicate itself 
as well as give rise to the specialized cells under appropriate conditions.36 Therefore, 
stem cells have the ability to self-replicate for indefinite periods, perhaps throughout the 
entire life of the organism. Unlike the large majority of cells of the body that are committed 
to a specific function, Stem cells are uncommitted and remain as such, until they receive 
a signal to generate specialized cells.36  
Stem cells can be classified by the degree of potential differentiation in: i) totipotent 
(cells that can give rise to an entire organism, including extra-embryonic annexes. A 
fertilized egg is the only totipotent stem cell), ii) pluripotent (cells with the ability to differ-
entiate into all the three germ layers, endoderm, mesoderm and ectoderm. Examples of 
pluripotent stem cell are embryonic stem cells (ESCs), derived from the inner cell mass 
of the blastocyst-stage of an embryo, and induced pluripotent stem cells (iPSCs)37 ob-
tained from differentiated adult cells transfected with at least four key genes, Oct3/4, c-
Myc, Sox-2 and Kfl-4, according to a procedure developed by Takahashi and Yama-
naka), iii) multipotent (they can differentiate only in some types of cells. Adult stem cells 
are multipotent stem cells able to differentiate into all the cell types of the tissue), iv) 
unipotent (they can produce only one cell type). 
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Adult Stem Cells (ASCs) 
Adult stem cells (ASCs) are undifferentiated cells that are found in differentiated adult 
tissues. During the past decade, ASCs have been found in tissues that were not previ-
ously thought to harbour them, such as the central nervous system (CNS). More recently, 
it has been reported that ASCs from one tissue appear to be capable of developing into 
cell types that are characteristic of other tissues. Thus, the new concept of ASCs devel-
opmental plasticity has emerged.38 The primary function of stem cells is to maintain ho-
meostasis, and, with limitations, to replace cells dying because of injury or disease. Gen-
erally, ASCs are maintained within uninjured tissues in a quiescent and undifferentiated 
state.39 Quiescent ASCs are activated upon tissue injury via soluble and mechanical sig-
nals emanating from the site of injury, leading to the production of transit amplifying pro-
genitors that in turn differentiate into functional mature cells capable of tissue regenera-
tion.39,40 A small population of amplifying ASCs exits the cell cycle and returns quiescent 
to maintain a reserve of ASCs that can respond to future demands.41 From an evolution-
ary perspective, quiescence may help to ensure a steady state number of ASCs available 
for tissue regeneration, and act as a protective mechanism against genotoxic 
stresses.42,43  
ASCs have been identified in many animal models and human tissues. The list of adult 
tissues reported to contain stem cells is growing and includes bone marrow (BM), pe-
ripheral blood, brain, spinal cord, dental pulp, blood vessels, skeletal muscle, epithelia 
of the skin and digestive system, cornea, retina, liver, pancreas, heart, and the CNS. The 
most abundant information about human ASCs comes from studies on the BM and blood. 
There are two major types of stem cells found in the BM: hematopoietic stem cells 
(HSCs) which generate blood cells, and mesenchymal stem cells (MSCs) that support 
haematopoiesis and can differentiate into multiple tissues of the three germinal layers.44 
HSCs are the cells that give rise to all the blood cells and derive from the mesoderm. 
HSC research began in the aftermath of the nuking on Hiroshima and Nagasaki. Inves-
tigations of irradiated mice demonstrated that they could be rescued from haematopoi-
etic insufficiency by injection of cell suspensions extracted from haematopoietic organs.45 
In the 1950s, it was demonstrated that the bone marrow cells were able to restore the 
blood cell system.46,47 Till and McCulloch in the 1960s quantitatively assessed the sen-
sitivity to radiation of bone marrow cells using a genetic labelling based on pre-irradiation 
at low dose, inducing non-lethal chromosomal breaks. In this way they observed the 
presence of multipotent stem cells in the bone marrow, with a clonogenic and self-re-
newing capacity, and able to generate cellular populations of the blood.48,49 The applica-
tions for this cell type include both autologous and allogeneic transplantation for neo-
plastic hematological pathologies (such as multiple myeloma,50 lymphomas and some 
types of leukemia51), solid tumors (such as osteosarcoma51), congenital dysmetabolic 
diseases (such as Crohn's disease52–54), immune deficiencies (such as systemic Lupus 
erythematosus55,56) and for the reconstitution of haematopoietic and lymphoid popula-
tions after myeloablative treatments.  
Mesenchymal stem cells (MSCs) originate from the mesodermal leaflet. With the pro-
gress of preclinical studies, MSCs have been shown to be effective in the treatment of 
many diseases, including immune diseases.57 These cells, indeed, have shown both the 
ability to heal lesions and immunomodulatory activity.58 The first was proved by the good 
efficacy of application in clinical and preclinical studies for: osteonecrosis,59 myocardial 
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infarction,60–62 liver failure,63,64 renal failure following ischemic injury,65,66 wound healing 
through retrieval of macrophages and endothelial cells,67 infantile osteogenesis imper-
fecta,68 osteoarthritis69–71 and pulmonary tuberculosis (in cases of severe cross-re-
sistance to drugs).72 
The importance of immunomodulatory activity, which has emerged in recent years, has 
led to the formulation of new potential uses. Some therapeutic applications are now 
found in early phase II trials, including treatments ranging from type-1 diabetes73 to 
Crohn's disease74.  
The mechanisms responsible for the properties of these cells are not fully understood 
but are based on the ability of MSCs to modulate classes of immune cells.67,75,76 Homing, 
potential differentiation, production of trophic factors and immunomodulators are the el-
ements at the centre of this research field. 
 
 
Stem cells in clinical practice: The Good Manufacturing 
Practice (GMP) 
Stem cells are used in regenerative medicine for their self-renewal and plasticity fea-
tures, i.e. the ability to proliferate without loss of stem potential and to differentiate into 
specialized cell types. In physiological conditions, stem cells are responsible for normal 
cell turnover, aimed at the renewal of cell populations residing in their own tissue. 
The knowledge of the signals responsible for maintaining the undifferentiated state or, 
on the contrary, inducing differentiation is fundamental in order to reproduce in vitro the 
essential conditions for the maintenance and expansion of these types of cells. Stem cell 
behaviour is controlled by the interactions between soluble factors, paracrine signals and 
molecules of the extracellular matrix that collectively characterize the endogenous niche 
of the tissue where the stem pool resides.77,78 
Understanding all these different regulatory systems is therefore the basic condition for 
expanding and appropriately controlling stem cell differentiation outside the body, both 
for basic research and for translational studies. 
The process for using stem cells in the clinic begins with basic research, to identify, 
isolate, expand in culture, characterize and differentiate the population of stem cells of 
interest. Preclinical studies following several phases follow: i) the functional test, which 
uses animal experimentation to test the regenerative abilities of the cells of interest, ii) 
the determination of the mechanism of action underlying the treatment and iii) the devel-
opment of methods for large-scale expansion and cell preservation for clinical trials. After 
the preclinical tests, the treatment is then submitted to clinical studies evaluating the 
safety, the appropriate route of administration in the patient population and the effective-
ness of the treatment, under the guidelines of Good Manufacturing Practices (GMPs).79,80 
GMPs are a guarantee of quality and sterility of the cellular lot, but also of safety and 
functionality of cell therapy. GMPs cover all aspects of the manufacturing process: stor-
age, transport, qualified and trained production and quality control personnel, adequate 
laboratory facilities, approved written procedures and instructions, traceability of the 
product. The guiding principle of GMPs is that the product has been made every time by 
the same procedures under the same conditions. Every step is carried out following 
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approved procedures, written as Standard Operating Procedures (SOPs), describing all 
the tasks performed in the manufacturing process.81 
In this context, the problems concerning the use of Foetal Bovine Serum (FBS) as a 
supplement in culture media have emerged.79,80 Indeed, although FBS-based culture 
media are conventionally applied, bovine serum constitutes a source of xenogeneic an-
tigens and a risk of contamination by zoonoses, viruses and prions.82 In addition, im-
portant ethical issues emerged, deriving from the method of collecting whey (because of 
suffering for the foetus from which it is extracted) and from the world demand constantly 
increasing (about 700,000 liters per year).83 For these reasons, the research for an al-
ternative supplement to the FBS is taking great interest in the scientific community. The 
aim is to find a serum-free in vitro culture and expansion system that contains all the 
components: amino acids, hormones, lipids, vitamins, buffering substances and growth 
factors.84 Furthermore, all components used must be animal-free. To replace FBS, nu-
merous studies now refer to “humanized” culture conditions. “Humanized” supplements 
include human serum (HS) or autologous plasma,85 or platelet derivatives, such as plate-
let-rich plasma (PRP) and the platelet lysate (PL).86 
The first cell therapy products were aimed at the regeneration of portions of coating 
epithelium irreversibly compromised by serious burns.87 In particular, the stem cells of 
the epidermis are taken and are induced in vitro to form flaps of skin that can be subse-
quently applied on the patient, allowing an almost total restitution to the full functionality 
of the tissue.88 A great work was done by the group of De Luca and could constitute a 
definitive resolution for people affected by epidermolysis bullosa (1,500 in Italy and more 
than 500,000 in the world). The proposed technique involves the treatment of autologous 
cells in vitro and manipulation of these with gene therapy aimed at replacing the dam-
aged genes responsible for the pathology phenotype.89 
Another important application is the use of limbal stem cells, which under normal con-
ditions are responsible for maintaining cellular populations of the cornea. Following 
burns, radiation or infections it is possible to use this cell type (with autologous modality) 
to regenerate the corneal epithelium and completely compensate the opacification.90 
Today the goal of new cell therapies is to formulate targeted treatments that take ad-
vantage of the specific characteristics of each cell type. The use of stem cells can play 
a fundamental role also in the treatment of pathologies currently lacking a definitive and 




A new point of view on stem cells: Extracellular Vesicles 
Although it has been demonstrated in recent years that most organ systems of the 
body have a resident pool of somatic, tissue-specific stem cells, in many cases of trau-
matic injury or disease, the quantity and potency of endogenous stem cell populations 
are insufficient to regenerate compromised tissues. As such, research has focused on 
exogenous or non-tissue-specific stem and progenitor cell sources for tissue repair and 
regeneration. Initially, efforts to use stem cells for this purpose centered on the directed 
differentiation of these cells to the intended cell phenotype, and functional improvements 
in several tissues were noted with cell transplantation and attributed to stem or progenitor 
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cell differentiation. More recently, however, it has become apparent that many of the 
functional improvements attributed to stem cells may be due to paracrine actions in the 
host tissue rather than cell differentiation and repopulation. A resultant shift in research 
has seen the emergence of studies aiming to elucidate the paracrine mechanisms un-
derlying tissue repair and regeneration with stem or progenitor cell transplantation.92 
Stem cells can communicate with nearby and distant cells through soluble factors and 
direct cell-cell contact, as well as via detached extracellular vesicles (EVs). These vesi-
cles possess properties of freely diffusing factors and the extensive membrane and cy-
toplasmic organization of cells. They range from approximately 30nm to 3,000nm in di-
ameter and have a distinct biomolecular composition and, therefore, functions that de-
pend on EV subtype, cell source, and conditions.93 
EVs were initially considered cellular debris or a way to excrete unneeded or toxic 
products from cells, but their ancient evolutionary origins and their conserved mecha-
nisms of generation indicate that EVs perform essential physiological roles in cell-cell 
communication.94,95 
EVs are membrane vesicles containing cytosol from the secreting cells enclosed in a 
lipid bilayer.96 To date, many subgroups of EVs have been defined. Although specific 
characteristics have been proposed for each EV subpopulation, there is currently no 
specific identification of the markers of each subgroup that is widely accepted in order to 
distinguish these populations. Added to this is the lack of standardized methods of iso-
lation and characterization. Because of the difficulties in the methods of isolation, the 
multidisciplinary nature of the research field, and the different ways of classification, there 
is currently no consensus on the nomenclature to be used to identify the various vesicle 
populations. Currently, three main subpopulations are generally considered: i) exo-
somes, ii) microvesicles, iii) apoptotic bodies. 
The most important criteria for the classification of EV are the dimensions, density, 
morphology, lipid and protein composition and the subcellular origin. 
Microvesicles have a diameter between 100 nm and 1.0 μm97 and they are formed as 
a result of the budding of the plasma membrane. Apoptotic bodies are vesicles released 
by apoptotic cells and they have a diameter between 500 nm and 2000 nm. Exosomes 
are “cup-shaped” vesicles with a diameter of 30-100 nm, they originate from the fusion 
of an endosomal compartment, the multivesicular body (MVB), with the plasma mem-
brane, that leads to the release of the vesicles presents in the MVB. 
 
 
Molecular composition of EVs 
As a consequence of their origin, exosomes contain endosome-associated proteins 
(e.g., Rab GTPase, SNAREs, Annexins, and flotillin), some of which are involved in MVB 
biogenesis (e.g., Alix and Tsg101).98  
Membrane proteins often are also enriched on EVs, such as tetraspanins, a family of 
>30 proteins that are composed of four transmembrane domains.99 Tetraspanins such 
as CD63, CD81, CD82, CD53, and CD37 were first identified in B cell exosomes.100 
Other studies confirmed that tetraspanins are abundant in EVs from other sources.101 
EVs are also enriched in proteins that associate with lipid rafts, including glyco-
sylphosphatidylinositol-anchored proteins and flotillin.102,103 In comparison to the plasma 
membrane, exosomes from a variety of cells102,104–106 are highly enriched in cholesterol, 
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sphingomyelin, and hexosylceramides at the expense of phosphatidylcholine and phos-
phatidylethanolamine.  
A major breakthrough was the demonstration that the cargo of EVs include both mRNA 
and miRNA and that EV-associated mRNAs could be translated into proteins by target 
cells.107,108 Recently, analysis of RNA from EVs by unbiased deep sequencing ap-
proaches demonstrated that, in addition to mRNA and miRNA, EVs also contain a large 
variety of other small noncoding RNA species, including RNA transcripts overlapping 
with protein coding regions, repeat sequences, structural RNAs, tRNA fragments, vault 
RNA, Y RNA, and small interfering RNAs.107,108 
 
 
Biogenesis of EVs and cargo selection 
Exosomes and microvesicles have different mechanism of biogenesis: exosomes are 
generated within the endosomal system as IntraLuminal Vesicles (ILVs) and secreted 
during the fusion of MVBs with the cell surface, whereas microvesicles originate by an 
outward budding at the plasma membrane.  
Exosomes generate in an early endosome: cargo is segregated at the delimiting mem-
brane of the endosome and the endosomal membrane buds inwards forming vesicles, 
called ILV. The endosomal compartment is now called Multi-Vesicular Body (MVB). The 
molecular machineries involved in the biogenesis of MVBs consist of conserved proteins 
assembled into four multiprotein complexes: endosomal sorting complex responsible for 
transport (ESCRT)-0, -I, -II, and -III, which associate with accessory proteins (e.g., Alix 
and VPS4). The ESCRT-0, -I, and -II complexes recognize and sequester ubiquitinated 
membrane proteins at the endosomal delimiting membrane, whereas the ESCRT-III 
complex is responsible for membrane budding.107,108 
Exosomes can also be formed in an ESCRT-independent manner, which was revealed 
by studies showing that MVBs are still formed upon depletion of components of the four 
ESCRT complexes.109 Exosome biogenesis and secretion do not require ESCRT func-
tion but are dependent on sphingomyelinase, an enzyme that produces ceramide.110 
Ceramide may then allow the generation of membrane subdomains,111 which impose a 
spontaneous negative curvature on the membranes. In addition, proteins of the tetra-
spanin family have been shown to regulate ESCRT-independent endosomal sort-
ing.112,113 Mechanistically, these proteins form clusters and dynamic membrane platforms 
with other tetraspanins and with different transmembrane and cytosolic proteins114 prob-
ably acting in the formation of the microdomains that will bud. Tetraspanins also regulate 
the intracellular routing of cargoes towards MVBs.115  
Thus, it seems that both ESCRT-dependent and ESCRT-independent mechanisms 
operate in exosome biogenesis, and their contributions may vary depending on the car-
goes, which recruit them, and the cell type.  
However, additional mechanisms contribute to the targeting of cargoes to exosomes. 
For example, the sequestration of cytosolic proteins into ILVs can result from co-sorting 
with other proteins, such as the chaperones heat shock 70kDa protein (HSP70) and heat 
shock cognate 71kDa protein (HSC70), which are found in exosomes derived from most 
cell types.112,113  
Apart from proteins, extracellular vesicles also carry nucleic acids, including RNAs 
(mRNAs and non-coding RNAs, including miRNAs) and DNA sequences.116,117 
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Interestingly, miRNAs have been shown to be differentially sorted to exosomes depend-
ing on their sequence (presence of specific motifs),118 which indicates that incorporation 
of nucleic acids into exosomes is regulated. 
The biogenesis of microvesicles, instead, requires several molecular rearrangements 
within the plasma membrane, including changes in lipid components and protein com-
position, and in Ca2+ levels.119 Ca2+-dependent enzymatic machineries including amino-
phospholipid translocases (flippases and floppases), scramblases and rearrangements 
in the asymmetry of membrane phospholipids (exposition of phosphatidylserine from the 
inner leaflet to the cell surface), which causes physical bending of the membrane and 
restructuring of the underlying actin cytoskeleton, which favour membrane budding and 
formation of microvesicles.120,121 In addition to lipids, cytoskeletal elements and their reg-
ulators are certainly required for microvesicle biogenesis. The activity of the RHO family 
of small GTPases and of the RHO-associated protein kinase (ROCK), which are im-
portant regulators of actin dynamics, induces microvesicle biogenesis in different popu-
lations of tumour cells.122 
It is still unclear how nucleic acids, which are generally found in microvesicles, are 
targeted to the cell surface. One possible mechanism revealed from studies of cancer 
cells suggests the involvement of conserved zipcode RNA sequence motifs in the 3’-
untranslated regions in mRNA targeting into microvesicles,123 but the details of this pro-
cess remain to be discovered. 
 
Figure 3 Release of MVs and exosomes. MVs bud directly from the plasma membrane, whereas exo-
somes are represented by small vesicles of different sizes that are formed as the ILV by budding into early 
endosomes and MVEs and are released by fusion of MVEs with the plasma membrane. Other MVEs fuse 
with lysosomes. The point of divergence between these types of MVEs is drawn at early endosomes, but 
the existence of distinct early endosomes feeding into these two pathways cannot be excluded. Red spots 
symbolize clathrin associated with vesicles at the plasma membrane (clathrin-coated vesicles [CCV]) or 
bilayered clathrin coats at endosomes. Membrane-associated and transmembrane proteins on vesicles are 
represented as triangles and rectangles, respectively. Arrows represent proposed directions of protein and 
lipid transport between organelles and between MVEs and the plasma membrane for exosome secretion.96 
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Release of EVs 
The machineries involved in scission/release of MVs from the plasma membrane and 
those implicated in the mobilization of secretory MVBs to the cell periphery, their docking, 
and fusion with the cell surface are still at an early stage of comprehension. These pro-
cesses require the cytoskeleton (actin and microtubules), associated molecular motors 
(kinesins and myosins), molecular switches (small GTPases), and the fusion machinery 
(SNAREs and tethering factors).124 
The final step of exosome secretion requires, instead, the fusion of MVBs with the 
plasma membrane to release ILVs as exosomes, a process probably mediated by 
SNARE proteins and synaptotagmin family members.125 A SNARE complex known to be 
involved in the exocytosis of conventional lysosomes consists of VAMP7 on the lyso-
somes, syntaxin 7 on the plasma membrane and the lysosomal regulatory protein syn-
aptotagmin 7.126 The process of exosome secretion has been demonstrated in several 




Interactions of EVs with recipient cells 
Functions of EVs in physiological and pathological processes depend on the ability of 
EVs to interact with recipient cells to deliver their contents of proteins, lipids, and RNAs. 
Specificity of target cell binding is illustrated by the finding that isolated B cell exosomes 
selectively bind follicular dendritic cells in lymphoid follicles.127 Similarly, EVs released 
by a human intestinal epithelial cell line interacted preferentially with dendritic cells rather 
than with B or T lymphocytes.128 The cellular and molecular basis for EV targeting is still 
undetermined, but several target cell–dependent and –conditional aspects are beginning 
to emerge. Target cell specificity for binding of exosomes (or other EVs) is likely to be 
determined by adhesion molecules, such as integrins, that are present in EVs. Differ-
ences in exosomal tetraspanin complexes also appear to influence target cell selection 
in vitro and in vivo,129 possibly by modulating the functions of associated proteins, includ-
ing adhesion molecules such as integrins.99  
After binding to recipient cells, EVs may remain stably associated with the plasma 
membrane or dissociate, directly fuse with the plasma membrane, or be internalized 
through distinct endocytic pathways. When endocytosed, EVs may subsequently fuse 




Exosomes from MSCs 
MSC exosomes, like exosomes in general, carry a complex cargo that includes nucleic 
acids, proteins and lipids. A key requisite of MSC exosomes as a mediator of MSCs’ role 
as stromal support cells would be their capacity to support maintenance of homeostasis 
within the tissue and yet be responsive to the external environment. This role is particu-
larly important when tissue microenvironment is altered by disease or injury leading to a 
disruption in tissue homeostasis which in turn compromises normal tissue function.130 
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Tissue homeostasis is influenced by the immune system. While activation of the im-
mune system is critical in the elimination of pathogens and removal of dead or injured 
cells during tissue injury or disease, its attenuation upon resolution of the injury or dis-
ease is equally critical in the well-being of the tissue. Prolonged immune activation be-
yond the resolution of injury or disease will result in excessive tissue damage or progress 
to an immune dysfunction disease. Therefore, immune homeostasis is a critical compo-
nent of tissue homeostasis. MSCs have been widely documented to exert suppressive 
and regulatory immunomodulatory effects on both adaptive and innate immune cells in 
an autologous and allogeneic manner.131 
To rationalize the effects of MSC efficacy against immune diseases, it was postulated 
that MSCs exert their efficacy through paracrine secretion of trophic mediators.132,133 
Several secreted factors have been proposed, namely interferon-γ (IFN-γ)132,133 and in-
doleamine2,3-dioxygenase (IDO),134 transforming growth factor (TGF)-β1, hepatocyte 
growth factor (HGF), IL-6, prostaglandin E2 (PGE2).132,133 
In recent years, exosomes have been increasingly reported as the principal therapeutic 
agent in MSC secretion that underpins the regenerative and immunomodulatory capa-




MSC extracellular products: the next generation thera-
peutics for osteoarthritis 
Osteoarthritis (OA) is a type of joint disease that results from breakdown of joint carti-
lage and underlying bone. The most common symptoms are joint pain and stiffness.136 
Causes include previous joint injury, abnormal joint or limb development, and inherited 
factors. Risk is greater in those who are overweight, have one leg of a different length, 
and have jobs that result in high levels of joint stress. Osteoarthritis is believed to be 
caused by mechanical stress on the joint and low-grade inflammatory processes.137 
Treatment includes exercise, efforts to decrease joint stress, support groups, and pain 
medications. 
MSC therapy to treat OA is presently under clinical testing. Based on the large number 
of clinical trials using MSCs for a wide range of disease indications, it is evident that 
MSC-based therapies are generally safe. Although MSC has not been approved for OA, 
the widespread use of MSCs to treat OA in pets and other animals138,139 provides a com-
pelling rationale to use MSC therapy to treat OA in human.  
The discovery that MSC secretome and exosomes mediate MSC therapeutic activity 
could radically transform MSC therapy by eliminating many difficult issues associated 
with using living cells as therapeutics. The use of viable cells carries inherent risks such 
as occlusion in microvasculature leading pulmonary embolism and death,140 transfor-
mation of transplanted cells into inappropriate cell types or cancer, immune rejection, 
proarrhythmic side effects,138,139 ossifications and/or calcifications.141 
A perennial risk of cell-based treatment is that it is considered a permanent treatment 
as the transplanted cells cannot be removed in event of adverse activity or upon disease 
resolution. The manufacture of cell-based therapeutics is also challenging as cell viabil-
ity, potency and transformation have to be monitored and maintained throughout the 
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manufacturing process, storage, and delivery to patient. Replacing cells with exosomes 
eliminates many of these challenges such as occlusion of blood vessels and generation 
of inappropriate cell types as exosomes are not viable and small. Unlike cell therapy, 
exosome treatment is not a permanent treatment and can be easily suspended when 
there are adverse effects or when the disease resolves. Exosome production is more 
amenable to process optimization. For example, the cell source for exosome production 
could be selected or genetically manipulated to generate a high exosome-yielding clonal 
cell line with infinite expansion potential to ensure reproducible cost-effective production 
of exosomes. All things considered, MSC exosome therapy for OA could potentially be 
a safer, cheaper and a more effective treatment modality than cell-based MSC therapy. 
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Aim of the thesis 
 
This thesis work is part of a European project that aims to build a robotic and automated 
system for the isolation, expansion and production of mesenchymal stem cells, accord-
ing to the rules of GMPs. The bone marrow is taken directly from the patient's pelvis and 
transferred into a sterile chamber, inside which a robotic arm performs all manipulations, 
to then provide the cellular product ready for therapy, in a closed system. This, combined 
with the use of serum-free culture media, could allow to obtain cellular products with 
reduced risk of contamination by the operator, thus ultimately constituting a material that 
can be spent in the clinic both for quantities of final product and for techniques of pro-
duction used. 
To date, limitations such as poor cell production, high production costs, incomplete 
standardization of production processes and the heterogeneity of isolated mesenchymal 
stem populations are the major obstacle to the clinical translation of cell therapy methods 
from functional studies.  
Cell therapy aims to solve the global problem of chronic diseases, especially those 
related to advanced age (osteoarthritis, diabetes, cardiovascular disease and osteopo-
rosis), using heterologous or autologous stem cells. Although up to now, their potential 
has hardly been implemented in the usual clinical application, the MSCs are considered 
a fundamental resource for cell therapy. These cells are in fact easy to isolate, with high 
capacity for ex vivo expansion and with proven immunomodulatory and differentiating 
activity.  
In recent years, the study of their secretome and the idea that it is mainly responsible 
for the beneficial effects attributed to these cells in vivo has also assumed relevance in 
clinical perspective. 
The aims of this work were: 
1. characterize the BMSCs grown in the GMP-facility, in FBS and serum-free me-
dium, compared with BMSCs grown in plastic adherence; 
2. characterize the secretome and the extracellular vesicles extracted from the 
BMSCs cultured in FBS and serum-free conditions; 
3. evaluate the immunomodulatory properties of FBS- and SF-hBMSC-CM/EVs 
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Chapter 1: Biological validation of human 
mesenchymal stem cells isolated in an auto-





The presence of non-haematopoietic stromal cells in the bone marrow (BM) able to 
migrate through the blood steam to injury sites where contribute to tissue regeneration 
was suggested by the German pathologist Cohnheim in 1867. He proved that these fi-
broblast-like cells were involved in collagen deposition during the normal processes of 
wound healing. This role has been widely confirmed many years later.142–144  
In the 1970s, Friedenstein and colleagues demonstrated the existence of non-hema-
topoietic stem cells within the bone marrow.145 After placing whole bone marrow in cell 
culture dishes, they observed that it was possible to select a population of non-hemato-
poietic cells thanks to their ability to adhere to the plastic. They also reported that the 
adherent cells were similar to fibroblasts, spindle-shaped and organized in foci of few 
cells, that began to proliferate rapidly.146 Since then, these cells were referred to as col-
ony-forming unit fibroblasts (CFU-F). In the following decades, many groups focused 
their research on this new promising field.147 The studies unveiled that these cells were 
multipotent, capable of self-maintenance and able to differentiate in chondrocytes, oste-
oblasts and adipocytes.143,148–155 These cells were named by Caplan as mesenchymal 
stem cells (MSCs) and this term immediately gained wide popularity.156  
Typically, human MSCs are isolated by plastic adhesion, after plating the whole bone 
marrow in a cell culture dish. Red blood and other hematopoietic cells are washed away 
after few days, leaving adherent, fibroblastic-like cells. Although BM is still the main 
source of MSCs, these cells have also been identified in adipose tissue,157 synovial mem-
brane,158 umbilical vein,159 umbilical cord blood160 and dental pulp.161  
Due to the heterogeneity of the isolation methods and the increase in sources of sup-
ply, it became difficult to compare studies of different research groups making necessary 
to establish some guidelines. Thus, in 2006 the Mesenchymal and Tissue Stem Cell 
Committee of the International Society for Cellular Therapy (ISCT) proposed the follo-
wing minimal criteria to define human MSCs: i) MSCs must be plastic-adherent; ii) phe-
notypically, MSCs must be positive for the surface markers CD73, CD90 and CD105, 
and negative for hematopoietic markers like CD45, CD34, CD14, CD19 and HLA-DR 
surface molecules; iii) they must be able to differentiate in chondrocytes, osteoblasts and 
adipocytes.151 
Easy isolation and expansion protocols, good potential of differentiation, low 
immunogenicity and the fact that they do not require matching in transplantation have 
placed MSCs as one of the most promising candidates for a wide variety of therapeutic 
applications.162–164 Furthermore, MSCs possess immunomodulatory properties, which 
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confer them the ability to suppress adaptive and innate immune responses through the 
secretion of anti-inflammatory cytokines such as IFN-γ, IL-1, or TNF-α.165–167 In addition, 
they exert trophic effects mediated by numerous growth factors and cytokines.168 How-
ever, the use of stem cells in clinical therapy is braked by several issues arising from the 
isolation methods and due also to the manipulation of the cells itself . One of the reasons 
is certainly their low frequency in the tissues of origin that allow to isolate only a very low 
quantity of cells.155 Therefore, in vitro expansion is required to obtain enough cells to 
meet the clinical demand, consequently many efforts have been focused on optimizing 
and improving these in vitro methods.169–171 Moreover, ex vivo expansion of MSCs leads 
to alterations in genome stability,172,173 epigenetics174,175 and functional abilities to differ-
entiate into osteogenic cells.176,177 
The main advantage of MSCs lies in the possibility of using them in both an autologous 
and an allogenic scenario. For autologous applications, given that less cells are needed, 
a scale-out approach can be followed. On the contrary, for allogeneic use, a scale-up 
approach needs to be applied, in which it is possible to produce a large number of cells 
in bioreactor systems and to create a bank for cell storage.178 However, many allogeneic 
processes still require manual intervention that has a significant impact on cost and qual-
ity, and the development of reproducible and consistent bioprocesses is still a key chal-
lenge. In all cases, the main challenge concerns the manipulation, processing and pro-
duction in aseptic and closed systems, which should be easy to use and ensure that 
products are safe and pure, as well as the standardization between different preparations 
that allows the development of reproducible, robust, and efficient culture processes.179–
181 In this scenario, in 2006 the European Medicines Agency (EMA) wrote the Good Man-
ufacturing Practices (GMPs), a code of standards concerning the manufacture, pro-
cessing, packing, release and holding of a product for clinical therapy.81 
In addition to the handling and safety issues, there are other factors which can signifi-
cantly impact the production of stem cell therapies, as the reagents and the medium 
employed.182 The medium is crucial for efficacy and safety of MSC culture and should 
maintain the phenotype, genotypic stability and functions of MSCs during multiple pas-
sages.181 Fetal bovine serum (FBS) is the most widely used supplement in almost all 
protocols. The use of animal derivatives for the handling of a clinical-intended product is 
highly chancy, due to prionic and viral contaminations and immune reactions of the pa-
tients.183 Indeed, the proteins of bovine serum could be internalized by the cells and 
subsequently recognized as stranger antigens, stimulating immunogenicity in the organ-
ism.184 Unfortunately, the thorough composition of the FBS is not known and there are 
often significant differences between lots, therefore it is difficult to identify which compo-
nents are liable of triggering an immune reaction. 
Theoretically, using human blood derivatives, the unwanted effects of the FBS constit-
uents should be eliminated or at least reduced. The scientific community has proposed 
FBS alternatives such as human serum, platelet-rich plasma (PRP) and platelet lysate 
(hPL) from blood transfusion-secured sources.185 These products have similar efficacy 
to bovine serum, as regards the isolation and expansion of human MSCs, and they allow 
to eliminate all the immunoreactivity issues derived from the bovine derivatives employ-
ment. Indeed, the proliferation is even higher than the one achieved by the classical 
culture conditions and the cell phenotype is almost the same.186,187 The use of human 
serum, however, brings back the same problems as bovine serum regarding the 
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composition variability among the donors, which may negatively affect production effi-
ciency. Furthermore, the functionality of MSCs obtained when changing the medium 
should be tested, given that the differentiation potential of MSCs could be affected using 
platelet lysate-supplemented medium. In addition, differences in immunological proper-
ties of MSCs produced using FBS or hPL have been reported.167 In addition, platelet 
derivatives must also be produced in transfusion centers with GMP approval, with a con-
sequent increase in costs. 
For these reasons, it seems mandatory to look for alternative, xeno-free formulations, 
which allow a culture yield comparable to that one obtained with classical protocols but 
removing all the problems of contamination and variability, and that can be used in the 
clinical settings. 
Ideally, a suitable substitute for FBS should present a low risk of contamination, low 
costs, easy availability and long shelf life.188 Some studies reported the use of a tank 
bioreactor for the expansion of MSCs in xenogeneic-free conditions with human se-
rum.189,190 There are already commercial xeno-free media FDA-approved, which guaran-
tee an effective growth of MSCs from adipose tissue and bone marrow grown in plastic 
microcarrier, as demonstrated in some studies.191 Unfortunately, the xeno-free media 
currently used select only a small sub-population of MSCs, which is able to survive under 
serum deprivation and then began to proliferate in serum-containing medium. This sub-
population represent a very early progenitor cells displaying longer telomeres .192 
In this context, the AutoStem project was proposed. The research is funded by the 
European Commission Horizon 2020 and it involves ten different European academic 
and industrial partners. The ambitious goal of this study is to develop a closed and auto-
mated robotic pipeline for the scaling-up and GMP-ready production of MSCs, in an 
aseptic ‘donor-to-patient’ system, practically a ‘StromalCellFactory’.193 
The study allowed the development of an automated pipeline for allogeneic stem cells: 
the bone marrow is taken directly from the donor's hip bone and transferred into a sterile 
chamber, where a robotic arm supports the isolation of the cells, which are kept in culture 
inside a bioreactor. Although multiple cell production systems are available,194 two of the 
major cell culture platforms have been considered, a small stirred vessel bioreactor, with 
approximately 1 L capacity, and microcarrier systems. Microcarriers provide a signifi-
cantly larger surface area per unit volume compared to other expansion platforms. The 
system also includes a steady process of cells amount, microenvironment and other pa-
rameters real-time monitoring. Thus, changes in pH, temperature and oxygen are felt by 
sensors to ensure efficient culture conditions. The development of this platform has ap-
pealing advantages, including obtaining substantial quantities of final product, the ap-
plicability in clinical therapy, in a short time and reduction of the risk of contaminations 
due to operator’s manipulation. In addition, this platform can develop bespoke, inter-
linked modular units which can be reconfigured and adapted to accommodate new pro-
cesses or take advantage of emerging technologies to facilitate cost- and risk-based 
continual process improvements.  
Another considerable innovation regards the culture medium used, which was a new 
generation, xeno-free medium, without animal derivatives.195 This was a chemically de-
fined xeno-free medium, contained known amount of Transforming Grow Factor β (TGF-
β1), Platelet Derived Grow Factor (PDGF) and basic Fibroblast Grow Factor (FGF-b). 
~ 24 ~ 
 
 
Bone marrow was obtained from the hip bone of healthy donors with the approval from 
the University College Hospital Galway Ethics Committee. The samples were transferred 
to the partners, and the cells were cultured in vitro using Standard Operating Procedures 
(SOPs) developed in a previous FP7 PurStem project. 
The goal of our group from University of Genoa, was to compare the traditional plastic 
adherent isolation and culture of MSCs with the cells isolated and cultured with Auto-
Stem’s protocols, using a fully defined growth medium, without FBS. The Plastic Adher-
ent hBMSCs (PA-hBMSCs) were characterized in terms of growth potential, surface phe-
notype, in vitro tri-lineage differentiation potential and in vivo osteogenic potential and 
compared to AutoStem cells. To evaluate the osteogenic potential in vivo, we used the 
MBCP+®, a biomaterial already tested in our laboratory in a recent study by R. Pereira. 
MBCP+® is a scaffold based on calcium phosphate (CaP) with a hydroxyapatite (HA)/β-
tricalcium phosphate (β-TCP) ratio of 20/80, with a good porosity that allows calcium ion 
releasing, sustaining the vascularization of the environment and the osteogenic differen-
tiation of the cells. 
 
 
~ 25 ~ 
 
 
1.2 Materials and Methods 
 
1.2.1 Human Bone Marrow Stromal Cells (hBMSC) cultures in plastic adherence 
Plastic Adherent human Bone Marrow Stromal Cells (PA-hBMSCs) were derived from 
hip bone marrow aspirates of healthy donors, after informed consent. The human sam-
ples were obtained from EU-AutoStem Consortium, after approval by the Clinical Re-
search Ethical Committee at University College Hospital, Galway, Ireland and processed 
at National University of Ireland Galway (NUIG). Briefly, cell nucleated fraction of bone 
marrow aspirate was suspended in α-MEM-Glutamax medium (Gibco, Waltham, MA, 
USA), supplemented with: i) 10% Fetal Bovine Serum (FBS, Gibco), 1 ng/ml Fibroblast 
Growth Factor-2 (FGF-2, Peprotech, London, UK) and 100 U/ml of Penicillin/Streptomy-
cin mixture (Euroclone) for standard culture conditions, ii) or with the AutoStem patented 
serum-free supplement and 100 U/ml of Penicillin/Streptomycin mixture. The cells were 
plated at a density of 1x106 cells/cm2. After at least 5 days, only PA-hBMSCs were at-
tached on the plastic, while all the blood cells and other debris were in suspension. Thus, 
the medium was discarded, the cells were washed with Phosphate Buffer Saline 1X 
(PBS) to remove all the refuse and the dishes were refilled with fresh medium. When 
culture dishes were confluent, PA-hBMSC were detached with trypsin-EDTA (Euroclone) 
and cryopreserved for the delivery to our laboratory. After arrival, we thawed the cells 
and 2.5 x 105 cells were plated in 100 mm dishes (density of 3000 cells/cm2) and grown 




1.2.2 Analysis of proliferation and Colony Forming Unit-Fybroblasts (CFU-F) assay 
To calculate the number of doublings (understood as number of cell replications) per-
formed by cells at each passage in culture, we cultured PA-hBMSCs in α-MEM supple-
mented with 10% FBS or with serum-free supplement. At the confluence, the cells were 
detached with trypsin-EDTA, harvested and counted with a Neubauer counting chamber, 
then they were re-plated, always at the same density of about 3000 cells/cm2. The base-
2 logarithm of the ratio between n° of counted cells and n° of plated cells was the number 
of doublings performed by the cells in that passage. The cells were maintained in culture 
for 30 days and, at the end, the data was put on a graph and expressed as n° of cumu-
lative doublings (i.e. every time point was the summation of all previous n° of doublings) 
vs. days of culture. This experiment was performed for all three primary cultures. 
Parallel to normal cell expansion, a CFU-F test was also performed, to test the clono-
genic potential. For this purpose, the cells were plated at a very low density (10 
cells/cm2). In this way, they spread on the plate surface as single cells, that form isolated 
colonies. After 2 weeks, the cells were fixed with 3.7% para-phormaldehide (PFA) for 10 
minutes, washed with PBS 1X and stained with 1% methylene blue in borate buffer (pH 
8.8) for 45 minutes. The colonies can be counted and observed under a microscope. 
The images were acquired with a scanner (Epson Scan) and then analyzed for the in-
tensity of pixels and for the colony area with the ColonyCounter plugin of the Software 
ImageJ. 






1.2.3 PA-hBMSC phenotypic characterization by flow cytometry 
For phenotypic characterization by flow cytometry, cells cultured in FBS-containing me-
dium and in serum-free medium were trypsinized with Tripsyn-EDTA, counted and di-
vided into several fluorimetric tubes (100,000 cells/tube). Cells were washed with PBS 
1X, centrifugated and then incubated with 1μl of specific antibodies conjugated with flu-
orescein isothiocyanate (FITC) or phycoerythrin (PE): CD31-FITC, CD34-FITC, CD45-
PE, CD73-FITC, CD105-PE, CD146-FITC, (Biosciences, San Diego, CA, USA), CD90-
PE, CD166-PE, CD106-PE, HLA-ABC-PE, HLA-DR-FITC (BD Pharmingen San Diego, 
CA, USA). The appropriate IgG-isotype controls, conjugated with FITC or PE (Biosci-
ence), were also used to stain the cells. The staining was run for 30 minutes a 4°C in the 
dark (to preserve the fluorochromes). After this time, the cells were washed with PBS 
1X, centrifugated and then resuspended in simple medium or PBS 1X for the analysis. 
Samples were run on Cyan ADP cytofluorimeter (Beckman-Coulter, Brea, CA, USA). 
Data were analyzed using FlowJo software and expressed as Log fluorescence intensity 
versus number of cells. Analysis was performed on all three different primary cultures at 




1.2.4 PA-hBMSCs differentiation assays 
 
PA-hBMSC in vitro adipogenic differentiation and staining protocol 
The adipogenic differentiation potential was tested at early stages (P2) by plating the 
cells at a density of 20,000 cells/cm2, in growth medium, i.e. α-MEM with 10% FBS or 
serum-free supplement. Cells were grown in an incubator at 37°C with 5% CO2, until the 
confluence was reached. After that, the growth medium was replaced with differentiation 
medium, containing the specific factors. For adipogenic differentiation, the cells were 
stimulated for 3 days with an induction medium, represented by DMEM High Glucose 
with 1μM Dexamethasone, 10μg/ml Insulin, 200μM Indomethacin, 500μM 3-Isobutyl-1-
Methyl-Xanthine (Sigma-Aldrich, St. Louis, MO, USA), 1% Penicillin/Streptomycin, 10% 
FBS, followed by one day of maintenance treatment (DMEM High Glucose, 10μg/ml In-
sulin, 1% Penicillin/Streptomycin, 10% FBS). Three total cycles of induction and mainte-
nance were repeated, and the cells were monitored over time by microscope observa-
tion, to verify the formation of small lipidic drops, looking like dark spot inside the cells.  
At the end the cells were fixed with calcium formolo for 20 minutes, washed with 60° 
isopropyl alcohol for 1 minute, and then stained with 0.5% Oil Red O (Sigma-Aldrich, St. 
Louis, MO, USA) solution in 60° isopropyl alcohol. After a washing with 60° isopropyl 
alcohol, followed by a washing with distilled water, it was possible to observe the intra-
cellular lipid drops dyed in red. The images were acquired with an Axiovert 200M micro-
scope (Carl Zeiss) within a few minutes after staining because the dye tends to spread 
rapidly. 
 




PA-hBMSC in vitro osteogenic differentiation and staining protocol 
The osteogenic differentiation was performed at early stages (P2) by plating the cells 
in a 24 multi-well plate, at a density of 20,000 cells/cm2, in growth medium. Cells were 
grown in an incubator at 37°C with 5% CO2, until the confluence was reached. After that, 
the growth medium was replaced with differentiation medium, containing the specific fac-
tors and the medium was changed twice a week for 7, 14 and 21 days. The differentiation 
medium consisted of DMEM Low Glucose with the addition of 10% FBS, 100nM Dexa-
methasone, 10mM β-glycerophosphate, 100μM ascorbic acid-2P (Sigma-Aldrich, St. 
Louis, MO, USA) and 1% Penicillin/Streptomycin. At the end of the treatment, the cells 
were fixed with 3.7% PFA for 15 minutes and stained with 2% Alizarin S red (Sigma-
Aldrich, St. Louis, MO, USA) solution for 10 minutes at the dark (putting the plate in a 
drawer). Alizarin S is a red dye that binds to calcium deposits. Images were taken with 
Axiovert 200M.  
Also, a quantification of Alizarin was performed by adding 200μl/well of 10% acetic acid 
and incubating the plate for 30 minutes on a shaker. The cells were subsequently 
scraped and the whole suspension was transferred in 1.5ml tubes. After vortexing for 30 
seconds, the tubes were heated at 85°C for 10 minutes (taking care to seal them with 
parafilm, to avoid any type of diffusion of acetic acid vapors), incubated on ice for 5 
minutes and finally centrifugated at 20,000g for 15 minutes. We transferred 200μl of the 
supernatants in new tubes and we neutralized the solution by adding about 30μl of 10% 
ammonium hydroxide (NH4OH, pH must be between 4.1 and 4.5) (Sigma-Aldrich, St. 
Louis, MO, USA). We read the Optic Density (OD) of the samples at the spectrophotom-
eter (BioSpectrometer® Eppendorf, Milan, Italy), at 405nm. The data were reported in a 
graph as OD of the treated (differentiated cells) – OD of the control (undifferentiated 
cells) vs. time.  
 
 
PA-hBMSC in vitro chondrogenic differentiation: pellet cultures 
For chondrogenic differentiation, cells grown in FBS-containing medium or serum-free 
medium were trypsinized and 250,000 cells were pelleted in a 15ml tube. Within 24h, 
cells should form a small pellet capable of differentiating into cartilage, if treated with 
Chondrogenic Medium (DMEM-HG, Dexamethasone 100nM, Ascorbic Acid-2P 50μg/ml, 
ITS supplement 1x, 1mM pyruvate sodium, TGF-β 10ng/ml). The medium was changed 
three times a week for 21 days. After that, the pellets were fixed with 3.7% PFA for 15 
minutes, washed in PBS and preserved in 70% ethanol until the histological analysis with 






1.2.5 Iodide propidium (PI) and a FITC-anti-annexin-V apoptosis detection 
PA-hBMSCs cultured in FBS-containing medium or in serum-free medium were ana-
lyzed using flow cytometry, after two passages in culture. Double staining for FITC 
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Annexin-V binding and Propidium Iodide (PI) was performed to determine if cells were 
viable, early apoptotic or apoptotic using the Annexin-V apoptosis assay kit (BD 




1.2.6 Karyotype analysis 
PA-hBMSCs cultures were tested at 25% confluence. Cells were incubated in Ham’s 
F10 (EuroClone, Milan, Italy) with 0.1mg/mL colcemid (Sigma-Aldrich, St. Louis, MO, 
USA) for 3 h, which can collapse mitotic spindles and prevent the completion of mitosis, 
to synchronize the cells and to arrest them at metaphase. The medium was removed 
and a hypotonic solution (75mM KCl, 17mM Na-citrate) added. Cells were then fixed with 
a solution of ethanol : methanol : acetic acid (1:2:1) and dried at 25°C and 45% humidity. 
Metaphase spreads were analyzed after staining with quinacrine (Sigma-Aldrich, St. 
Louis, MO, USA) for karyotyping using Cytovision 3.93.3 Applied Imaging. Analysis was 





1.2.7 Assays for neoplastic transformation in vitro and in vivo 
To confirm that PA-hBMSCs did not possess malignant properties, in vitro colony assay 
formation and in vivo tumorigenesis analyses were performed. For in vitro testing, PA-
hBMSC cultured in FBS-containing medium and in serum-free medium at P2 were plated 
at a density of 10,000 cells/35-mm Petri dish in methyl-cellulose media hematopoietic 
stem cell (HSC)-CFU basic (Miltenyi Biotech, Bergisch Gladbach, Germany). After 14 
days of incubation, CFU-cells (CFU-C) were scored using an inverted microscope. The 
positive control used was the human breast cancer MDA-MB-231 cell line. 
In vivo tumorigenesis was assessed with PA-hBMSCs at P2 expanded from two donors 
in the two different culture conditions. For each PA-hBMSCs preparation, the same dose 
of cell (1x106, resuspended in 50μl of physiological solution) was injected subcutane-





1.2.8 In vivo neo-bone formation into ceramic scaffolds with PA-hBMSCs  
To assess the in vivo osteogenic potential, we associated PA-hBMSCs to a biomaterial 
for bone formation, the MBCP+®. This is a calcium phosphate ceramic scaffolds provided 
by Biomatlante SA, (Vigneux-de-Bretagne, France). This biomaterial is characterized by 
granules with a ratio of 20% HA and 80% β-TCP, a total porosity of 70% with a distribu-
tion of 25% of micropores (less than 10µm) and 75% of mesopores and macropores 
(over 10µm, mean size of macropores 300-600µm).  
PA-hBMSCs cultured in both serum-free and FBS-containing medium at P2 were tryp-
sinized and 2,000,000 of cells were pelleted in 15 ml tubes. The pellet was resuspended 
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in 20μl of fibrinogen and loaded onto the biomaterial granules (MBCP+®). Then we added 
10-15μl of thrombin which polymerizes the scaffold granules together with the cells in-
side. A construct (about 0.5cm Ø) is obtained that can be implanted subcutaneously in 
immunodeficient mice. 
The ectopic bone formation assay was adopted. CD-1 mice (CD-1 nu/nu; Charles 
River, Wilmington, Massachusetts, Stati Uniti) were anesthetized with an intraperitoneal 
injection of ketamine/xylazine mixture, surgical sites were cleaned with Mercurochrome, 
and subcutaneous pockets for each implant were created in the animal back. Ceramic-
hBMSCs constructs were implanted subcutaneously in the pockets and the wound was 
closed with chirurgical metallic agraphes (7,5 x 1,75mm, Michel). Groups of 6 animals 
were sacrificed after 2 months by CO2 saturation and the implants harvested for further 
analysis. All animals were maintained as required by the Italian Ministry of Health in 





1.2.9 Histological techniques 
In vivo implants are recovered following the sacrifice of the animals, fixed with PFA 
3.7%, decalcified and then included in paraffin.  
Decalcification is essential for histologically analyze samples of bone or cartilage, 
which would otherwise be hard to be included in paraffin. Decalcification were done with 
a 0.5M EDTA pH 8 solution, which sequester all the calcium, making the sample "softer". 
Inclusion in paraffin involved a phase of sample dehydration with ethanol steps at in-
creasing concentration (from 70% up to absolute EtOH), followed by a permeabilization 
phase in xylene and passages in liquid paraffin to growing temperatures (around 40, 50 
and 60°C). At the end of the three phases, the sample was included in paraffin blocks. 
4-5 μm serial sections were cut with microtome (Leica RM2165) and sections were 
stained with specific histological staining. 
 
 
Hematoxylin & Eosin and Goldner thrichromic stainings 
To verify bone formation within the implants, we performed a Hematoxylin & Eosin 
staining on the sections obtained from our samples. Hematoxylin stains in purple the 
negatively charged cellular elements such as nucleic acids, membrane proteins, nuclei. 
Eosin, on the other hand, colors in pink the positively charged components such as cel-
lular proteins, mitochondrial proteins and collagen fibers, thus highlighting the cytoplasm 
and extracellular matrices.  
The sections intended for staining must necessarily be deparaffined and re-hydrated 
following the descending scale of the alcohols: we started with xylol I, II, III for 7 minutes 
each one and subsequently we transferred the sections into absolute ethanol I and II, 
95% ethanol I and II, ethanol 90% (5 minutes each one) and finally distilled water. After 
this step of re-hydration, we stained the slides with hematoxylin for 4 minutes (this time 
is quite variable based on the type of sample to be colored). The sections were washed 
in running water, then with basic water (distilled water with the addition of some drops of 
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NH3), which determined a slight color change of the hematoxylin turning to blue. We 
stained the slides with eosin for 30 seconds, we washed them in distilled water, and we 
dehydrated quickly through the ascending scale of the alcohols (ethanol 95%, absolute 
ethanol, up to the xylols). Lastly, the slides were sealed with cover slides using Eukitt 
(Bio-Optica, Milan, Italy), an acrylic mounting medium for cytological and histological 
slides. 
We stained the samples also with Goldner thrichromic staining, by using the Goldner 
thrichromic kit (Bio-Optica, Milan, Italy). We carried out it according to manufacturer’s 
protocol. 
Images were obtained with a phase-contrast Axiovert 200M microscope (Zeiss).  
 
 
Vascular and bone histomorphometric assays 
Calcium phosphate ceramics were fixed, decalcified and routinely embedded in paraf-
fin as described above. To visualize and quantify vascular structures in the calcium phos-
phate ceramics, in the paraffin embedded samples 5μm sections were cut and stained 
with Mallory’s trichromic (Bio-Optica, Milan, Italy) according to manufacturer’s instruc-
tions. Five nonconsecutive sections per sample were observed in transmitted light. Fiji 
ImageJ software was used to calculate the number of vessels per ROI through the fol-
lowed steps: (i) vessel perimeter was manually defined; (ii) vessels were counted; (iii) 
number of vessels per ROI determined.  
To determine bone deposition, 5μm sections were H&E stained. Five nonconsecutive 
sections per sample were analyzed using Fiji ImageJ software to calculate bone matrix 
deposition area as follows: bone and scaffold areas were delimitated and the ratio be-




Immunoperoxidase of human osteocalcin was performed using a polyclonal rabbit-anti-
human OCN (1:100 in 10% Normal Goat Serum) (Abcam, Cambridge, UK). Immunobind-
ing was detected with biotinylated secondary anti-rabbit (1:300 in 10% NGS) (Dako, Ag-
ilent, Santa Clara, USA) and streptavidin-peroxidase (1:500 in 10% NGS) (Jackson Im-
munoResearch, Cambridge, UK). Peroxidase activity was visualized by 3-Amino-9-ethyl-
carbazole (AEC) chromogenic substrate (Sigma-Aldrich, St. Louis, MO, USA).  






1.2.10 hBMSCs isolation on carriers in a small stirred vessel bioreactor (i.e. spin-
ner flasks) 
Three different bone marrow-derived hBMSC donor lines were isolated from bone mar-
row aspirates using a bioreactor at University of Aston. 
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Small stirred vessel bioreactors (i.e. spinner flasks) were used in this study to evaluate 
the growth of hBMSCs on two different attachment substrates: on Xuri attachment sub-
strates (i.e. waffle macrocarriers; GE Healthcare) and on polystyrene substrates (i.e. 
SoloHill Plastic microcarriers; Pall Life Sciences).  
The spinner flasks were siliconized prior to start the experiments to ensure no cell at-
tachment will occur on the glass vessel and the cells will only attach to the provided 
attachment substrates (i.e. microcarriers).  
Microcarriers were weighed to provide a surface area of 500cm2 per spinner flask in a 
total volume of 100ml. The microcarriers were sterilized by autoclaving and prior to cell 
inoculation, they were initially pre-conditioned in medium for at least 1 hour to allow the 
protein absorption for facilitating cell attachment. Cells were then inoculated at 6,000 
cells/cm2. The first medium exchange (50%) was performed at day 3 in culture and then 
every other day. Microcarriers were stirred continuously at the minimum stirring speed 
necessary to suspend all particles which was assessed to be 30rpm.  
The Xuri macrocarriers were acquired from the manufacturer as sterile packs pre-
weighed to provide a 500cm2 surface area. One pack was used per spinner flask in a 
total volume of 100ml of medium. Macrocarriers were transferred to the spinner flasks 
and cells were inoculated at 4,000 cells/cm2. Medium changes (100%) were performed 
every other day. A continuous spin/rest cycle of 1minute stirring at 60rpm, followed by a 
rest of 45 minutes, was performed in order to allow cells to attach to the provided sub-
strates, but also to allow for a homogeneous environment and minimize concentration 




1.2.11 Analytical techniques used for culture monitoring in the spinner flasks 
In the macrocarrier culture system, cell attachment and proliferation were monitored by 
phase contrast microscopy or nuclei staining with DAPI and visualization under a fluo-
rescence microscope. Cell morphology was further assessed by fixing the cells, followed 
by staining with 1% Crystal Violet solution. Cell growth was assessed by cell counting 
after enzymatic dissociation. Briefly, waffles with cells could settle, medium was aspi-
rated and replaced with a phosphate saline solution and two consecutive washes were 
performed. Enzymatic dissociation of the cells from the waffles was done by trypsiniza-
tion for 10 minutes. Cell dissociation was confirmed by observation under the micro-
scope. 
In the microcarrier culture system, culture monitoring was done by taking 0.5ml sam-
ples and imaging under either a phase contrast inverted microscope or a fluorescent 
microscope after staining cells with a Live/Dead viability/cytotoxicity kit (Life Technolo-
gies, Thermo Fisher Scientific). For Live/Dead staining, cells-microcarriers samples were 
first washed once with PBS 1X and then incubated with the Live/Dead staining solution 
for 40 minutes at 37°C in a humidified incubator. The Live/Dead staining solution was 
prepared according to the manufacturer’s instructions. Post-incubation, the Live/Dead 
staining solution was removed and the cells-microcarriers samples were resuspended in 
PBS 1X and visualized under a fluorescence microscope. Live cells are distinguished by 
the presence of ubiquitous intracellular esterase activity, determined by the enzymatic 
conversion of the virtually non-fluorescent cell-permeant calcein AM to the intensely 
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fluorescent calcein. The polyanionic dye calcein is well retained within live cells, produc-
ing an intense uniform green fluorescence in live cells (ex/em ~495 nm/~515 nm). The 
other component of the kit, ethidium homodimer (EthD-1) enters cells with damaged 
membranes and undergoes a 40-fold enhancement of fluorescence upon binding to nu-
cleic acids, thereby producing a bright red fluorescence in dead cells (ex/em ~495 
nm/~635 nm). EthD-1 is excluded by the intact plasma membrane of live cells. 
Additionally, every other day in culture, two independent samples of microcarrier-cell 
suspension were taken for cell counting on the Nucleocounter cell counter (Chemome-
tec). First, the cells were lysed from the microcarriers and then stabilized and counted 




1.2.12 Statistical analysis 
In vitro statistical analysis was performed using t-test. Error bars indicate standard de-
viation (S.D.). In vivo statistical evaluation was done by using the data from explants of 
n=6 animals for each experimental condition. The data were analyzed by t-test. Error 
bars indicate standard deviation. For all in vitro and in vivo figures, a p-value 0.05 was 
considered to be statistically significant. GraphPad software was used as work program. 
  






1.3.1 PA-hBMSCs grown in vitro in FBS-containing medium or in serum-free me-
dium show different growth kinetics, morphology, and clonogenic potential 
The isolation of hBMSCs from bone marrow was performed by our partner at National 
University of Ireland, Galway (NUIG). The plastic adherent hBMSCs (PA-hBMSCs) ob-
tained from 3 different donors were isolated and cultured in presence of FBS or in serum-
free medium. The cell populations obtained after one passage were sent by NUIG to our 
laboratory. hBMSCs proliferation studies and colony forming unit assay (CFU-F) were 
performed in both culture conditions.  
We observed a slightly higher cell proliferation in serum-free grown populations. The 
doubling rate in the first 10-15 days of cell expansion was very similar in both conditions 
(Fig.4A), but after 20 days we observed a strong increase of proliferation in PA-hBMSCs 
grown in serum-free medium (10-12 doublings at 30 days vs. 5-7 in FBS group). 
Some differences in morphology were found between the two culture conditions 
(Fig.4B). The cells cultured in presence of FBS exhibited a spindle-shaped, fibroblastic-
like morphology. In serum-free, already at the first passage, the cells had a less elon-
gated morphology, appeared smaller and less branched.  
To test the PA-hBMSCs clonogenic potential, cells were plated at low density (10 
cells/cm2) and cultured for two weeks in both culture conditions. After 14 days, the colo-
nies observed in FBS-containing medium were large, with densely packed cells, while in 
serum-free medium we observed only a few small colonies (Fig.4C). 
Figure 4 A) Proliferation of PA-hBMSCs growth in presence of FBS or in serum-free medium (3 donors). 
Growth kinetics is expressed as the number of cell duplications in relation to the culture time.  
B) Microscope images showing the morphology of cells. Image acquired with a phase contrast Axiovert 
200M microscope.  
C) PA-hBMSCs clonogenic potential: CFU-F assay performed in presence of FBS and in serum-free 
medium. Images have been acquired with scanner Epson 360. The quantification of colony area and in-
tensity was performed with Fiji ImageJ software. The error bars represent standard deviations (S.D). (*) P< 
0.05, t-test.  
FBS  SERUM-FREE 
B 
C 
FBS SERUM-FREE  
A 
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1.3.2 PA-hBMSC cultured in FBS-containing medium or serum-free medium have 
a similar phenotype with different expression of CD106 
A consistent phenotype is also important when isolating and culturing hBMSCs for ther-
apeutic applications. Therefore, we examined the phenotype of PA-hBMSCs cultured in 
presence of FBS or in serum-free conditions after two passages. This analysis was car-
ried out using flow cytometry to measure markers expressed on the surface of PA-hBM-
SCs. 
PA-hBMSCs cultured in FBS-containing medium and serum-free medium showed little 
variation in the highly expressed markers such as CD73, CD90, CD105, CD146 and 
CD166. In agreement with the International Society of Cell Therapy (ISCT) criteria, both 
cultured MSC preparations were negative for CD45, CD34 and CD31. The markers with 
the largest differences between different culture conditions were CD106 and HLA-DR, 
which are completely absent in serum-free cultures (Fig.5A and B).  
CD106 or vascular cell adhesion molecule-1 (VCAM-1) is a member of the immunoglobu-
lin superfamily that interacts with the integrin VLA4. The CD106/VLA4 interaction medi-
ates both adhesion and signal transduction. Although fibronectin facilitates the attach-
ment of the cells to the bottom of the plates, it was previously shown as not necessary 
for the isolation, attachment and expansion of serum-free hBMSCs and so it was re-
moved from the process. Based on the lower expression of CD106 in PA-hBMSCs cul-
ture in serum-free medium reported here, we tried to isolate serum-free hBMSCs in pres-
ence of fibronectin to investigate its role in the lack of CD106 expression. hBMSCs were 
isolated from bone marrow and cultured in absence of fibronectin (W/O), on fibronectin 
pre-coated plates (FC) or in presence of fibronectin in the medium (FNM). These cells 
were assessed for their CD106 expression along with the other surface markers men-
tioned above. Negligible expression of CD106 was observed in these serum-free cell 
groups and the other markers do not undergo substantial modifications (Fig.5C). 




Figure 5 A) Flow cytometry analysis of PA-hBMSCs cultured in the presence of FBS-containing medium (two 
rows on the top) or in serum-free culture medium (two rows on the bottom). Dark gray-filled histograms indicate 
antibody staining; light gray histograms showing the isotype control staining are also shown. The percentage of 
positive events is reported. Results are expressed as log fluorescence intensity a.u. vs. number of cells and are 
representative of three independent experiments.  
B) The average percentage of positive events of each marker is reported in a histogram, indicating the mean + 
SD. (*) P(CD106) < 0.05 t-test Bonferroni.  
C) Surface marker expression of serum-free PA-hBMSCs isolated in the presence or absence of fibronectin. 
W/O: without fibronectin, FNM: fibronectin in the medium, FC: fibronectin pre-coated flasks. 
A B 
C 
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1.3.3 Differentiation potential: PA-hBMSCs cultured in serum-free medium showed 
a higher osteogenic potential in vitro 
To be effective in therapeutic applications, cultured hBMSCs must retain their ability to 
differentiate into different cell types. Therefore, we assessed the ability of the PA-hBM-
SCs cultured in presence of FBS or in serum-free conditions to form new bone tissue 
(osteogenesis), adipose tissue (adipogenesis) and cartilage (chondrogenesis). 
To compare the cartilage matrix deposition capacity of PA-hBMSCs cultured in pres-
ence of 10% FBS or in serum-free medium, we performed pellet culture with the cells at 
passage 2. All cell populations formed the typical three-dimensional spherical aggre-
gates. Nonetheless, aggregates formed by the PA-hBMSCs grown in serum-free condi-
tions were larger than those made by cells cultured in FBS. Pellets formed by both hBM-
SCs cultures presented some metachromatic toluidine blue staining after two passages, 
suggestive of the presence of cartilage proteoglycans (Fig.6A). 
In the adipogenic-stimulated cultures, the presence of intracellular lipid granules after 
3 weeks of induction was weakly observed in both cell culture conditions. Analysis was 
performed in triplicate (Fig.6B).  
A different scenario is proposed regard to osteogenic potential. Under both FBS or 
serum-free culture conditions, cells displayed the ability to differentiate toward osteo-
blasts and exhibited morphological changes. After 21 days of differentiation, calcium 
mineral deposition was evident, but with some differences between the two culture con-
ditions. The cells grown in serum-free medium deposit bone matrix faster respect to FBS-
cultured cells, indeed they start to differentiate already after 1 week of induction, showing 
a massive mineral deposition after 3 weeks of treatment (Fig.6C). These data were con-
firmed also by the quantification of alizarin by spectrophotometric analysis (405nm, 
Fig.6D). 
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Figure 6 Differentiation assays. A) Chondrogenic differentiation performed by pellet culture, stimulated for 
21 days, for the FBS and serum-free cultures. Pellets were embedded in paraffin and stained with toluidine 
blue.  
B) Adipogenic differentiation revealed by formation of lipid droplets stained with Oil Red O in PA-hBMSCs 
grown in FBS-containing medium or in serum-free medium.  
C) Osteogenic differentiation revealed by alizarin staining after 7, 14 and 21 days of induction in PA-hBM-
SCs cultured FBS-containing medium or serum-free culture medium; negative control (Und), cultured without 
any differentiation stimulus, is also shown.  
D) Alizarin was extracted with 10% acetic acid and the samples were read at 405nm at 7, 14 and 21 days 
and put on a graph with OD (treated-control) vs. time. The error bars show the SD. (*) P< 0.05 t-test Bonfer-
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1.3.4 Serum-free media culture played a protective role on PA-hBMSCs  
To exclude any negative effect on cell viability caused by serum-free medium, we per-
formed a cytofluorimetric assay, using two fluorescent molecules, propidium iodide (PI) 
and a FITC-anti-annexin-V antibody, so we compared by double staining the percentage 
of apoptotic cells in both cell culture conditions.  
PI is a very voluminous molecule that is unable to cross the plasma membrane. It can 
enter only dead cells, because following the process of cell death, the plasma membrane 
is fragmented.196 Once within the cell, it binds to  double stranded DNA by intercalating 
between base pairs. The annexin is instead a typical marker of apoptosis because it 
binds phosphatidylserine (PS), molecule which expression in the cell surface is in-
creased during early apoptotic stage. PS is normally only found on the intracellular leaflet 
of the plasma membrane in healthy cells, but during early apoptosis, membrane asym-
metry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin 
V can then be used to specifically target and identify apoptotic cells.197,198 Therefore, 
following the staining, we can have three different conditions: cells positive only to An-
nexin-V (cells in early apoptosis), double-positive cells (dead cells) or double-negative 
cells (living cells). 
Differences were observed between the cell populations grown in the presence of FBS 
or in serum-free medium, with a significant increase of alive cells and decrease of apop-
totic cells in serum-free samples (Fig.7A and B). 
A cytogenetic analysis was performed on PA-hBMSCs cultured in presence of 10% 
FBS or in serum-free medium; 20-25 metaphases were analyzed at passage 2. We did 
not observe any chromosomal abnormality and a normal karyotype was observed in both 
groups analyzed (Fig.7C). 
PA-hBMSCs tumorigenic potential was also tested in vitro by anchorage-independent 
growth in methylcellulose media and in vivo. PA-hBMSCs grew as adherent cells when 
plated in FBS-containing medium or in serum-free medium when plated in standard cul-
ture dishes, but no CFU-C was detected when both groups of cells were transferred to 
the methylcellulose semi-solid media (Fig.7D). The control tumorigenic human breast 
cancer cell line MDA-MB-231 formed colonies as expected.  
For the in vivo tumorigenesis study, 1x106 of PA-hBMSCs for each condition were im-
planted in 12 NOD/SCID mice, which were monitored for up to 12 weeks. No mouse 
developed tumors. Mice neither showed any sign of illness, nor macroscopic nodules. 
Finally, mice were sacrificed, and no anatomical gross abnormalities were observed by 
autopsy. 
 






































Figure 7 Detection of apoptosis by concurrent staining with FITC-anti-Annexin V and PI. PA-hBMSCs 
grown in FBS-containing medium or serum-free medium were stained with Annexin V-FITC conjugate and 
PI and their fluorescence were measured using flow cytometry (A) and quantified (B). The histogram shows 
the mean + SD, (*) P< 0.05, t-test.  
C) Karyotype analysis of PA-hBMSCs cultured in FBS-containing medium or serum-free medium;  
D) In vitro tumorigenesis test: anchorage independent growth in methylcellulose for PA-hBMSCs cultured 
in FBS-containing medium or serum-free medium and human breast cancer cells MDA-MB-231 (positive 
control). Black arrow indicates the colony. 
* 
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1.3.5 In vivo neo-bone formation into ceramic scaffolds: PA-hBMSCs cultured in 
serum-free medium showed a higher osteogenic potential in vivo 
We tested PA-hBMSC capacity to form bone within engineered constructs based on 
CaP scaffolds with a specific (HA)/β-tricalcium phosphate (β-TCP) ratio (MBCP+®; 
20/80), following the well-established ectopic bone formation model, consisting in the 
subcutaneous implantation of cell-ceramic constructs in immuno-compromised CD-1 
mice.199 PA-hBMSCs from the two different cultures seeded on CaP ceramic gave rise 
to tissue-engineered ossicles with mineralized bone detectable after two months. More 
specifically, the hematoxylin and eosin staining (Fig. 8B/a,b) and the Goldner trichromic 
staining (Fig.8B/c,d) of the explants revealed that cells of both culture conditions differ-
entiated in osteoblast (Ob), which organized in an ordered row of cells on the top of the 
scaffold walls. These cells started to deposit bone matrix to form a dense connective 
tissue with parallel oriented fibers within which some cells were incorporated to become 
osteocytes (Oc). However, the explants obtained from serum-free cultured cells 
(Fig.8B/d) presented structures in which the new formed bone is organized around the 
bone marrow (Bm). These structures were indeed absent in the scaffolds seeded with 
cells cultured in FBS-containing medium. 
Histomorphometric quantification of new-formed bone showed statistically significant 
differences between the two ceramics, with a higher rate of bone formation in scaffolds 
seeded with serum-free cells (Fig.8C).  
To investigate possible mechanisms of the enhanced in vivo osteogenesis in CaP scaf-
folds seeded with PA-hBMSCs, we looked for the presence of osteocalcin taking ad-
vantage of antibodies directed against the human protein. Only within the scaffolds 
seeded with cells grown in serum-free medium there was an upregulation of osteocalcin 
protein expression, indicating a high process of bone formation and mineralization (Fig 
8B/e,f). 
Detection, visualization and quantification of blood vessels sprouted inside the CaP 
scaffolds seeded with PA-hBMSCs grown in either FBS-containing medium or serum-
free medium were performed using Mallory Trichrome staining (Fig.85D). After 2 months, 
the scaffolds seeded with FBS cells appeared penetrated by a higher number of small 
sprouted vessels than MBCP+® seeded with serum-free cells (Fig. 8E). However, in the 
latter the vessels tended to be larger than those found in in the FBS group cells, although 
the differences did not reach the statistical significance. 
  






















































Figure 8 Osteogenic differentiation of PA-hBMSCs on calcium phosphate (CaP) scaffolds.  
A) Experimental design: Cells grown in FBS-containing medium or in serum-freemedium were loaded on an 
MBCP+® ceramic scaffold and implanted subcutaneously in CD-1 nude mice.  
B) Histological sections of explants stained with: Hematoxylin and Eosin (H&E), MBCP+® with FBS-PA-hBMSCs 
(a) and serum-free-PA-hBMSCs (b) after 2 months. Goldner Trychromic staining of MBCP+® with FBS-hBMSCs 
(c) and serum-free-PA-hBMSCs (d) after 2 months. Osteocalcin immunostaining of MBCP+® with FBS-PA-hBM-
SCs (e) and serum-free-PA-hBMSCs (f).  
C) Quantification of bone area formed by the two different cell populations within the scaffolds. The error bar 
represents standard deviations. (*) P value < 0.05, t-test. 
D) Detection of the presence of vascular structures into scaffolds seeded with the two different populations of 
PA-hBMSCs. Histological sections of explants were stained with Mallory’s trichome: a) and b) are sections of 
MBCP+® seeded with PA-hBMSCs cultured in FBS-containing medium or in serum-free medium, respectively. 
Blood vessels are pointed by arrows.  
E) On the left, quantification of the number of blood vessels inside both different implants. Error bars represent 
standard deviations. (***) P value < 0.001, t-test. On the right, quantification of the area of blood vessels inside 
both different implants.  
Scale bar = 100μm. Sc – Scaffold; Oc – osteocytes; Ob – osteoblasts and BM – bone marrow.  
 
E 
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1.3.6 PA-hBMSCs growth on waffle macrocarriers in a small stirred vessel biore-
actor (spinner flasks) 
The type of bioreactor that was chosen to be used in the AutoStem pipeline is a small 
stirred vessel bioreactor with approximately 1L capacity (Fig.9A). Two different types of 
attachment substrates were tested for cell attachment and growth in agitated conditions 
in small stirred vessel bioreactors: Xuri attachment substrates (waffle macrocarriers; GE 
Healthcare) and polystyrene substrates (SoloHill Plastic microcarriers; Pall Life Sci-
ences). 
GE waffle macrocarriers are hexagon-shaped, porous structures of approximately 
0.5cm in size (Fig.9B) made of polystyrene. When inoculated on the macrocarrier waf-
fles, the PA-hBMSCs successfully attached and proliferated when cultured in both FBS-
containing and serum-free medium. As the culture progressed, the cell number in-
creased, as shown in Figure 9C by the increase in the DAPI-stained nuclei. In addition, 
cell growth appeared increased when cells were cultured in serum-free medium, com-
pared to those grown in FBS-containing medium. Cell morphology studied after crystal 
violet staining, when cultured on the waffles appeared to be more rounded and less elon-
gated than the one that is typical for PA-hBMSCs (Fig.9D), which is a possible indicator 
of a stressed phenotype of PA-hBMSCs in the stirred vessel possibly due to agitation. 
Overall, cell growth in the bioreactor, shown as cumulative population doublings over 
2 passages, was lower than cell growth in monolayer culture, although the difference did 
not reach the statistical significance. However, this difference in cell growth could be-
come significant with the increase of cell passage. Additionally, an increased cell growth 
was observed when using a serum-free medium compared to FBS-containing medium 
(Fig.9E). 
  




























Figure 9 A) Image of the stirrel vessel bioreactor. 
B) Representative images of the GE macrocarriers without cells. 
C) Representative images of macrocarriers with cells at different time points when cultured in either FBS-
containing medium or serum-free medium. Cell nuclei were stained with DAPI and appeared as blue. Scale 
bars represent 500 μm. 
D) PA-hBMSCs morphology when cultured on waffles in FBS-containing medium or in serum-free medium.  
E) PA-hBMSCs growth in serum-containing medium (SC) and serum-free medium (SF) over 2 consecutive 
passages in monolayer culture (i.e. T-flasks) compared to 3D culture in the bioreactor. On the left, cumulative 
population doublings. on the right, predicted cell yield. ***p≤0.001 as determined using two-way ANOVA and 
Bonferroni m͛ultiple comparisons post-hoc test. 
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1.3.7. PA-hBMSC growth on plastic microcarriers in a small stirred vessel bioreac-
tor (spinner flasks)  
Unlike the waffle macrocarriers, the Plastic microcarriers are micrometer sized polysty-
rene beads of an average size of approximately 180μm and densities slightly higher than 
water (~1.1 g/cm3). When inoculated onto the beads, PA-hBMSCs successfully attached 
and proliferated. Indeed, 4 days post-inoculation the cells attached on the provided mi-
crocarriers as demonstrated by the presence of bridges between the cells and the mi-
crocarriers (white arrows in Fig.10A). Even though not all the microcarriers had visible 
cells on them or signs of bridging, we cannot state for sure that those microcarriers were 
not inhabited with cells because the Plastic microcarriers are opaque and don’t allow for 
clear visualization of the cells. However, a better method for cell visualization on these 
microcarriers, as well as an indicator of cell viability, is a Live/Dead fluorescent staining 
kit. Fig. 10B shows fluorescent microscope images of PA-hMSCs cultured on microcar-
riers. Live and healthy cells with intact membranes were stained green, while dead or 
cells with damaged membranes were brightly red. 
The cells were kept in culture for 10 days. At day 2 in culture, there was a slight drop 
in cell number. This decrease in cell density is normal, as during the first 2 days the cells 
adapt to the new culture environment, which in this case is an agitated environment and 
the attachment substrates are represented by microcarriers. However, from day 4 on-
wards, cell growth increased progressively, reaching the peak at day 10 when the cell 





Figure 10 A) PA-hMSCs on Plastic microcarriers at day 4 in culture.  
B) PA-hMSCs growth on Plastic microcarriers over 10 days in spinner flasks. Data are expressed as mean + 
SD. 
C) Live/Dead staining of PA-hMSCs cultured on Plastic microcarriers in spinner flasks in FBS-containing me-
dium. Images were acquired at day 5 in culture. Scale bar represents 100 μm. 
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1.3.8 In vivo neo-bone formation into ceramic scaffolds of 3D-hBMSCs 
To validate the AUTOSTEM cell differentiation potency, we received from Aston Uni-
versity hBMSCs cultured in presence of 10% FBS using the Mobius Bioreactor and 
agreed Autostem protocols. The cells were thawn and cultured for few days (3 days) 
before their implantation in nude mice. 
We tested the capacity of hBMSCs derived from the bioreactor (WP4) to form bone 
within engineered constructs based on CaP scaffolds with a specific (HA)/β-tricalcium 
phosphate (β-TCP) ratio (MBCP+®; 20/80), following the well-established ectopic bone 
formation model, consisting in the subcutaneous implantation of cell-ceramic constructs 
in immuno-compromised CD-1 mice. We compared the bone formation of these cells 
with PA-hBMSCs. PA-hBMSCs from the two different cultures (FBS and serum free 
seeded condition) on CaP ceramic gave rise to tissue-engineered ossicles with mineral-
ized bone detectable after two months. More specifically, the hematoxylin and eosin 
staining (Fig.11A) of the explants revealed that cells of both culture conditions can form 
bone, which organized in an ordered row of cells on the top of the scaffold walls. These 
cells started to deposit bone matrix to form a dense connective tissue with parallel ori-
ented fibers within some cells incorporated. However, the explants obtained from serum-
free cultured cells presented structures in which the new formed bone is organized 
around the bone marrow. These structures were indeed absent in the scaffolds seeded 
with cells cultured in FBS-containing medium. A similar situation is detectable in the ex-
plants with 3D-hBMSCs.  
Histomorphometric quantification of new-formed bone showed that 3D-hBMSCs had a 












Figure 11 Osteogenic differentiation of 3D-hBMSCs on calcium phosphate (CaP) scaffolds compared 
to PA-hBMSCs  
A) Histological sections of explants stained with Hematoxylin and Eosin. 
B) Quantification of bone area formed by the three different cell populations within the scaffolds. The 
error bar represents standard deviations. (*) P value < 0.05, t-test. 
Scale bar = 100μm.  
 




1.3.9 Automated pipeline for PA-hBMSC production in GMP 
The basic concept of the AutoStem platform design is shown in Figure 12. It basically 
consists of a sterile chamber, where a robotic arm supports the isolation of the cells, 
which are kept in culture inside a bioreactor.  It is expected two bioreactors, a bioreactor 
for cell isolation (seeder bioreactor), from which the cells are moved to another bioreactor 
for expansion (expander bioreactor).  
Additionally, there are also area for freezing and storage of cryovials, refrigerators and 
disposables. 
Cell counting will be performed using the NucleoCounter NC-30000 cell counting de-
vice. A centrifuge, a pipetting device and a decapper are also present. 
The platform and the modules possess functionalities that are analogous to the labor-
atory equipment used in the manual process. This way the process can be transferred 
and adapted on the Autostem platform in a straightforward manner. 
The automated process can be divided into the distinct steps. Bone marrow that is 
aspirated from a donor at the clinical site is collected in a 50 mL tube. The bone marrow 
aspirate is then shipped at room temperature to the production facility, where it is then 
introduced in the platform (step 1) and seeded into the seeder bioreactor (step 2). After 
subsequent cultivation in the seeder (step 3) and the expander bioreactor (step 4), cells 
are harvested and filled into cryo vials (step 5). The product is then stored at – 80°C until 





Figure 12 Schematic drawing of the Autostem platform layout. The platform consists of two separate 
chambers. 






The multipotency and anti-inflammatory effects of mesenchymal stem cells (MSCs) 
make them attractive for cell therapy in regenerative medicine. MSCs are multipotent 
cells residing in the bone marrow and can, under appropriate conditions, differentiate 
into mesenchyme-derived cell types (osteoblasts, chondrocytes and adipocytes.200–203 
hBMSCs are harvested and expanded in large quantities without causing donor site mor-
bidity. They represent a rich source of cells to be used in the development and improve-
ment of tissue engineering and regenerative medicine.204 hBMSCs retain their multi-lin-
eage differentiation capacity until stimulated by specific cytokines and growth fac-
tors.205,206 The use of hBMSCs for the treatment of osteoarthritis and bone defects has 
been described in large animal models207–209 and in humans.204,210–213 
In most cases, hBMSCs expansion must be performed prior to their application for 
clinical use. However, in vitro expansion of hBMSCs could modify cell properties, in-
crease the time to cell implantation and costs, and it is subject to a great deal of regula-
tion.172,173,175–177 Until now, the field of cell therapy lacks advanced methods for isolation 
and large-scale expansion of stem cells that are automated, scalable and closed. Choos-
ing the culture system and culture medium used to produce cells are key steps toward a 
safe, scalable, and cost‐effective expansion bioprocess for cell therapy purposes.189 Pre-
sent cell culture medium supplements, in most cases based on animal sera, are not fully 
satisfactory. The adoption of an animal-free culture medium is particularly relevant in 
establishing culture conditions for isolation and expansion of cells intended for clinical 
applications.214 
We proposed here a novel approach to produce MSCs from human bone marrow with 
xeno-free and aseptic culture system, for therapeutic cell manufacturing and delivery.  
It is known that maintenance of a steady population doubling time is critical for amplifi-
cation of MSCs to treat diseases. Classical isolation by plastic adherence of hBMSCs in 
our xeno-free medium compared with isolation with conventional FBS-containing me-
dium showed that, although both culture conditions sustain proliferation of PA-hBMSC, 
the cells grown in serum-free medium presented a higher and significantly stable prolif-
eration rate, suggesting that the culture using the xeno-free medium could harvest more 
cells in a faster time compared to FBS-containing medium. This data are consistent with 
that reported for Adipose-Derived MSC (ASCs) and human dental pulp stem cells cul-
tured in chemically defined xeno-free media.215,216 
Before to move into automated cell production, we needed to set up and validate the 
culture conditions to be used for AutoStem cell manufacturing. To achieve this goal, we 
first isolated and expanded PA-hBMSCs in our xeno-free medium and compared these 
cells with those isolated and expanded using the conventional FBS-containing medium. 
We found that, although both culture conditions sustain proliferation of PA-hBMSC, the 
cells grown in serum-free medium seem to have a lower clonogenic potential, as shown 
in Fig.1C in the CFU-F assay. This lower clonogenic capacity of the cells grown in serum-
free medium could be related to their decreased expression of the surface markerCD106. 
The decreased CD106 may lead to a lower adhesion of PA-hBMSC to substrate resulting 
in a decrease in CFU numbers. It has been reported that the expression of CD106 varies 
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with the tissue source of MSCs. Thus, while CD106 is expressed by bone marrow-de-
rived MSCs, it is absent on MSCs derived from adipose and other tissues, 217 Therefore, 
the decrease in CD106 induced by serum-free medium may not affect the efficacy of the 
PA-hMSCs grown in this conditions on their clinical applications. 
Importantly, the absence of expression of HLA-DR observed in cells grown in FBS-
containing medium was also observed in those cells grown in serum-free medium. This 
is a key point given the involvement of this protein in the activation of the immune system 
and the consequent rejection of allografts.218 Therefore, these results suggest that the 
PA-hBMSCs grown in our serum-free medium would not elicit an alloreactive response, 
making them an excellent candidate for their use in clinical settings, for instance in MSC-
based therapy for osteoarthritis. However, it has been shown that MSCs expressing 
HLA-DR are poorly immunogenic and, in addition, possess immunosuppressive capac-
ity.167,219 For these reasons, it has been suggested that HLA-DR should not be consid-
ered a critical release criterion for MSCs.220 Therefore, it would be useful to study if cells 
grown in our serum-free medium retain the capacity of suppressing T-cell proliferation 
and consequently the immunosuppressive ability.  
A second important finding of our research regarding the potential use of our serum-
free medium to expand PA-hBMScs intended to be use in clinical settings is that the cells 
isolated and grown in our medium displayed a strong osteogenic potential. Thus, these 
cells showed earlier differentiation and faster bone matrix deposition than the cells grown 
in FBS containing medium, as confirmed by both in vitro and in vivo differentiation as-
says. Interestingly, the in vivo ectopic bone formation assay suggests that PA-hBMSC 
cultured in serum-free medium can give rise to an engineered human bone, with wide 
bone matrix and bone marrow areas (Fig. 5B). Also, chondrogenic potential seemed to 
be higher in serum-free conditions, given that the cells grown in FBS-containing medium 
formed smaller pellets than those grown in serum-free medium (Fig. 3A). 
In this scenario, we suggest that serum-free culture conditions allow to expand a PA-
hBMSC population that preserve the trilinage potential but with enhanced osteogenic 
potential respect to its adipogenic and chondrogenic potential.  
The safety of the MSCs intended to be used in clinics should be carefully assessed 
before the administration of the cells to the patients. Karyotyping or other tests evaluating 
genetic stability are often performed.  In our study, the karyotypic profile of the cells cul-
tured in serum-free medium was normal. However, karyotype abnormalities have been 
reported previously but usually at late passages and the cells enter into senescence 
without transformation, regardless of chromosomal alterations.221  
Here we have validated a reproducible clinically-compliant culture method for PA-hBM-
SCs using a free-serum medium, which allows the production of high quantities of PA-
hBMSCs at a low passage (P2). These cells fulfill all MSC criteria, including the ability to 
differentiate into chondrocytes, osteoblasts and adipocytes and the lack of expression of 
HLA-DR. In addition, these PA-hBMSCs meet safety criteria given that they retain ge-
netic stability and do not induce tumor formation.The validations described supported the 
use of the AutoStem platform to isolate hBMSCs in serum-free culture condition. 
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Chapter 2: Isolation and characterization of 
secretome and EVs of hBMSCs grown in 




Intercellular communication is an essential hallmark of multicellular organisms and can 
be mediated through direct cell–cell connection or by a paracrine way, with signalling 
molecules that are released in the extracellular space and caught by other cells to pro-
duce a cellular response.96 In the last two decades, a third mechanism has been brought 
to light, involving extracellular vesicles (EVs).96,222–227 EVs are vesicles surrounded by a 
phospholipidic bilayer containing signaling molecules, including proteins, lipids, DNA, 
RNA and miRNA. They have reparative and anti-inflammatory properties and they are 
released from cells into the extracellular space. Although the production of apoptotic 
bodies during apoptosis has been long known,228 the fact that also perfectly healthy cells 
shed vesicles from their plasma membrane has only recently become recognized. In-
deed, the release of EVs was initially thought to be only a process to discard nonfunc-
tional cellular components, but increasing evidence suggests that EVs play a critical role 
in intercellular communication.229 
The secretion of EVs is a process that appears to be conserved throughout evolu-
tion.96,230 Indeed, cells from different organisms, including all eukaryotes (from amoe-
bae,231 Caenorhabditis elegans,232,233 and parasites234–237) but also prokaryotic cells and 
virus,238–240 have been demonstrated to release vesicles into the extracellular environ-
ment.  
The first observations of the EVs and their relevance occurred simultaneously in vari-
ous physiological contexts, without the awareness that this form of communication is a 
universally shared biological structure of the cells. Initially, the EVs were observed in 
1946 by Chargaff and West in plasma, as procoagulant particles of platelet derivation241, 
and identified as "platelet dust" by Wolf in 1967.242 First studies also included matrix 
vesicles identified by Anderson in 1969 in cartilage and correlated with the calcification 
of epiphysis.243 Between 1970 and 1980, other studies have identified EVs released in 
plasma by microvilli cells of rectal adenoma,244 or virus-like particles identified in bovine 
serum of cell culture medium245,246 and vesicles, later called prostasomes, in the seminal 
fluid.247,248 Around the same period, first findings were made of membrane fragments 
acting as pro-coagulants and derived from tumors.249,250 
A big breakthrough came in 1983 with the work done by Stahl and Johnstone, focusing 
on reticulocytes maturation in red blood cells.251,252 These experiments led to the discov-
ery of what is now called transferrin cycle and they allowed to clarify the mechanism of 
secretion of extracellular vesicles. Reticulocytes begin their journey in the bone marrow 
as erythroblasts. They discharge their nuclei before taking up residence in the blood 
where they continue the maturation process for 24 to 36 hours to become bona-fide red 
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blood cells.251 As reticulocytes mature into red blood cells, they selectively lose or discard 
certain membrane proteins, such as transferrin receptors.253,254 Transferrin (Tf) is a gly-
coprotein that circulates in the blood of all vertebrates and is responsible for delivering 
iron to cells. Iron is required by all cells but especially reticulocytes, that contain high 
concentrations of haemoglobin, an iron binding protein.255 Each transferrin molecule 
(apo-transferrin) bonds avidly two atoms of iron (holo-transferrin). Transferrin in turn, 
binds to transferrin receptor (TfR) with very high affinity.256–258 Using transferrin bound to 
gold particles,252 or anti-TfR antibodies,259 and using electron microscopy to follow the 
fate of the endocytosed receptor during its trafficking in the cell and subsequent release, 
the two groups found that Tf-TfR complex is internalized into a multivesicular endosomal 
compartment by endocytosis and most of the gold staining corresponding to the receptor 
was associated with the small internal bodies (approximately 50 nm in diameter). Once 
in the endosome, iron is reduced, dissociates from its transferrin carrier and is trans-
ported by facilitated diffusion into the cytoplasm, where it is incorporated into the heme 
group of hemoglobin. Tf stays bound to the TfR on the small bodies, which are released 
upon fusion of the endosomes with the plasma membrane of the cells.256,257 The net 
effect of the transferrin cycle is to transport iron into cells, while sparing and recycling 
the iron carrier protein Tf. These and the following studies suggested that this novel form 
of secretion was the way in which TfR were discarded from maturing reticulocytes.260 In 
1987, the term exosome was first used to describe small membrane vesicles formed by 
vesiculation of intracellular endosomes and released by exocytosis.260 
More than a decade later, Raposo et al. showed that these vesicles, isolated from the 
B lymphocytes transformed by the Epstein-Barr virus, were antigen-presenting particles 
and they were able to induce a response in T cells.261  
Following these pioneering studies, EVs were isolated from most types of cells and 
biological fluids, including blood,261–264 urine,265–267 saliva,268,269 breast milk,270–273 amni-
otic fluid,274–278 ascites,279–281 cerebrospinal fluid,282,283 bile,284,285 and semen.247,286–289 
A significant forward step in EVs research field was achieved in 2011 by members of 
the International Society of Extracellular Vesicles (ISEV) aimed at unifying the nomen-
clature and methodology to isolate the EVs. The data indicated that the content, size and 
composition of the EVs membrane are very heterogeneous and dynamic and depend on 
the state of the secreting cell and environmental conditions. To date, many subgroups of 
EVs have been defined, such as apoptotic bodies, microparticles, microvesicles, shed-
ding vesicles, ectosomes, exosomes and exosome-like vesicles.95,229 
 Although characteristics have been proposed for each EVs subpopulation, there is 
currently no specific identification of the markers of each subgroup that is widely ac-
cepted in order to distinguish these populations. Added to this is the lack of standardized 
methods of isolation and characterization. Furthermore, isolation procedures generally 
fail to purify specific types of vesicles but instead produce complex mixtures of various 
types of EVs. Because of the difficulties in the methods of isolation, the multidisciplinary 
nature of the research field, and the different ways of classification, there is currently no 
consensus on the nomenclature to be used to identify the various vesicle populations. 
For example, vesicles are often called referring to the cell or tissue of origin, for example, 
dexosomes (exosomes derived from dendritic cells),290,291 prostasomes (vesicles derived 
from the prostate),247,286 vesicles of the matrix (from bone, cartilage and atherosclerotic 
plaques),243,263,292–294 or synaptic vesicles (vesicles released by neurons),295–300 or 
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referring to their size (microparticles, microvesicles, nanovesicles, nanoparti-
cles),239,301,302 or to their proposed functions (calcifying matrix vesicles, argosomes, tole-
rosomes),303–306 or simply to their presence outside the cells (ectosomes, exosomes, ex-
ovesicles, exosome-like vesicles).307,308 Although the nomenclature is still a matter of de-
bate,309 the terms ectosome, shedding vesicle, microparticle and microvesicles generally 
refer to 150-1.000 nm vesicles released by budding from the plasma membrane (PM). 
The term exosome was initially used to name vesicles ranging from 40 to 1.000 nm re-
leased by a variety of cultured cells and carrying 5’-nucleotidase activity.310 However, 
this term was adopted after the experiments of the 1980s for small (30-100nm) vesicles 
of endosomal origin released as consequence of the fusion of multivesicular bodies 
(MVBs) with the PM.251,259,260 Since then, the term exosome has undergone a rise in 
popularity, with increasing numbers of articles choosing this term to designate EVs.  
Mesenchymal stems cells (MSCs) and all types of stem cells also secrete extracellular 
vesicles, which have different therapeutic activities and may represent a breakthrough in 
clinical stem cell therapy.305-314  
The paracrine effect of MSCs was first described in 1996 when Haynesworth et al. 
reported that MSCs synthesize and secrete a broad spectrum of growth factors, chemo-
kines and cytokines that could exert significant effects on nearby cells.324 This funding 
gave start to numerous studies on the effects of the MSCs secretome which reported 
that these secreted factors enhance arteriogenesis,325 protect against ischemic renal and 
limb tissue injury,326 promote neovascularization,327 increase angiogenesis,328,329 pro-
mote human cartilage regeneration in vitro,330 prevent apoptosis induced by perinatal 
hypoxia-ischemia in neuronal cells,331 attenuates neuroinflammation and improves func-
tional recovery in a model of acute spinal cord injury (SCI)332 and protect hippocampal 
neurons from oxidative stress.333 These studies have provided the basic foundation of 
the paracrine hypothesis, according to which MSCs exert their therapeutic function not 
mainly through their differentiating potential but rather via their ability to secrete certain 
essential factors.334–341 Much of the initial efforts to identify the active therapeutic agent 
in MSC secretion focused therefore on small molecules such as growth factors, chemo-
kines, cytokines and miRNA.342 
In 2009, Bruno et al. demonstrated that MSCs secrete 80nm-1μm microvesicles that 
protect against acute tubular injury.343 In 2010, Lai et al. subsequently showed that MSCs 
secrete a specific class of EVs with endosomal origin, a diameter of 40-100nm344 and 
expressing exosome-associated markers such as Alix, Tsg101, tetraspanins such as 
CD9, CD63 or CD81. 
MSC exosomes are distinguished from those of other cell derivation for specific prote-
omic profiles (857 unique gene products) and vesicular RNA (more than 150 identified 
miRNAs).135 miRNAs and proteins are involved in many cellular processes, such as com-
munication, inflammation, exosomal biogenesis, metabolism, tissue repair and regener-
ation.135,345–353 MSC exosomes have the potential to support the maintenance of the tis-
sue microenvironment. This role is particularly important when the tissue microenviron-
ment is altered by a disease or a lesion leading to failure of tissue homeostasis.130 On 
the other hand, microenvironment influences MSCs paracrine signaling (e.g., protein and 
RNA profile of exosomes). Therefore, controlling MSCs growth conditions by modifying 
the growth factor composition, oxygen tension and mechanical properties could directly 
influence the paracrine activity of MSCs354–356 
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Despite the extensive research done in the field of the EVs as therapeutic tools, there 
are still many issues to be solved. One of the main troubles is related to the isolation and 
culture method. The vast majority of cell cultures are indeed conducted in media con-
taining foetal bovine serum (FBS), which brings along a large number of extracellular 
vesicles of bovine derivation, which may represent a contamination in the final sample. 
The EVs isolation methods currently available do not allow the discrimination between 
vesicles derived from cells and those arising from the culture medium supplement, pre-
cluding the achievement of an accurate and artefacts-free characterization. Moreover, 
from the point of view of a large-scale production for use in clinical therapy, it is important 
to have cellular products completely free of animal derivatives. In many studies, FBS 
was preventively ultracentrifuged to eliminate its vesicular component. However, these 
methods were not completely efficient, as they do not guarantee the obtainment of a 
completely exosome-free serum and, in addition, some FBS-deriving extracellular RNAs 
(exRNAs) can keep in culture and interfere with analysis.357 In this scenario, it seems 
important to develop a clean, exosome-free culture system.  
In our study we use a novel xeno-free cell culture medium for isolation and expansion 
of human MSCs in plastic adherence and in bioreactors. As part of an ambitious Euro-
pean project with the ultimate goal of developing one GMP-StromaCellFactory, our goal 
was to compare the traditional plastic adherent isolation and culture of MSCs with the 
cells isolated and cultured with AUTOSTEM’s protocols, using a fully defined growth me-
dium, without FBS, as previously described. The second important deliverable provided 
the isolation and characterization of extracellular vesicles in the two different culture sys-
tems.  
Hypoxia (1% O2) has been reported to elevate exosome production in a number of cell 
types in vitro. This hypoxia-induced increase in exosome secretion is controlled by hy-
poxia-inducible factor-1 alpha (HIF-1α) and is independent of apoptosis.358 Hypoxia not 
only affect the quantity of exosomes produced but also the composition of their content 
and, therefore, their therapeutic potential. Thus, MSCs cultured under hypoxia (< 5% O2) 
showed an altered protein expression pattern compared to MSCs cultured in 
normoxia.354 Furthermore, in a murine hind limb ischemia model, intra-arterial injection 
of MSCs cultured under both normoxic or hypoxic conditions promoted revascularization, 
but the functional recovery of mice that received hypoxia preconditioned MSCs was 
achieved earlier.359 These findings indicate that preconditioning MSCs in different oxy-
gen environments may potentiate their tissue regenerative properties. 
Plastic-Adherence human MSCs (PA-hMSCs) were cultured under normoxia (20% O2) 
or under hypoxia (1% O2) to enhance EVs production. The hypoxia culture conditions 
mimic in part the native micro-environment of the cells in case of damage or stress, re-
sulting for example from a stroke: the hypoxic environment that is generated stimulates 
the stem cells to proliferate and differentiate, as well as to secrete factors that attract 
other neighboring cells that participate in the repairing of the damage tissue.360–362 The 
use of hypoxia therefore allowed us to study the paracrine activity of MSCs, which seems 
to be more active in the presence of hypoxic stress. 
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2.2 Materials and Methods 
 
2.2.1 Human Bone Marrow Stromal Cells (hBMSC) cultures in plastic adherence 
Plastic Adherent Human Bone Marrow Stromal Cells (PA-hBMSCs) were derived from 
hip bone marrow aspirates of healthy donors, after informed consent. The human sam-
ples were obtained from EU-AUTOSTEM Consortium, after approval by the Clinical Re-
search Ethical Committee at University College Hospital, Galway, Ireland and processed 
at National University of Ireland Galway (NUIG). Briefly, cell nucleated fraction of bone 
marrow aspirate was suspended in α-MEM-GlutaMax medium (Gibco, Waltham, MA, 
USA), supplemented with: i) 10% Fetal Bovine Serum (FBS, Gibco), 1ng/ml Fibroblast 
Growth Factor-2 (FGF-2, Peprotech, London, UK) and 100 U/ml Penicillin/100μg/ml 
Streptomycin mixture (Euroclone) for standard culture conditions, or ii) with the AUTO-
STEM patented serum-free supplement and 100 U/ml Penicillin/100μg/ml Streptomycin 
mixture. The cells were plated at a density of 1x106 cells/cm2 in T75cm2 flasks or 100mm 
dishes. After at least 5 days, only PA-hBMSCs were attached on the plastic, while all the 
blood cells and other debris were in suspension. Thus, the medium was discarded, the 
cells were washed with Phosphate Buffer Saline 1X (PBS) to remove all the refuse and 
the dishes were refilled with fresh medium. When cells were confluent, PA-hBMSC were 
detached with trypsin-EDTA (Euroclone) and cryopreserved for the delivery to our labor-
atory. After arrival, cells were thawed, and 2.5 x 105 cells were plated in 100mm dishes 
(density of 3000 cells/cm2) and grown in an incubator at 37°C with 5% CO2. The medium 




2.2.2 Isolation and culture of human Arthicular Chondrocytes (hACs) 
Human Articular Chondrocytes (hACs) were obtained from human femoral head biop-
sies of healthy patients, after informed consent. First, the sample was processed with 
the help of a scalpel, in order to withdraw the cartilaginous coating from the joint. The 
pieces obtained were then cut into smaller pieces of about 3mm x 3mm, then they were 
transferred in a 50ml tube, washed with PBS 1X and  resuspended in 1-2mL of a mix of 
enzymatic digestion, consisting of 1mg/mL hyaluronidase (Sigma-Aldrich, Saint Louis, 
Missouri, USA), 400U/mL collagenase I (Wortington Biochemical, Lakewood, NJ ), 
1000U/mL collagenase II (Wortington Biochemical) and 0.25% trypsin (GiBCo) in Dul-
becco’s Modified Essential Medium (DMEM) High Glucose (EuroClone) w/o FBS. A first 
digestion of 30 minutes at 37°C was carried out to relax the matrix and it was therefore 
discarded. Various serial digestions were then performed, each one for at least 60 
minutes at 37°C in agitation, to obtain individual cells. After each digestion, the superna-
tant was recovered, resuspended in 10mL of DMEM with 10% FBS to block the enzy-
matic activity and centrifuged for 10 minutes at 1200rpm. The isolated hAC were seeded 
in 1-2 wells of a 6-well plate, in DMEM High Glucose with 10% FBS 2mM L-Glutamine 
(EuroClone), 100U/ml Penicillin/100μg/ml Streptomycin, 1mM Na-pyruvate (EuroClone) 
and 10mM HEPES (EuroClone). In each well a liquid hyaluronidase quota of 8U/mL was 
also added, in order to break up any aggregates of cells still present in the suspension. 
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The medium was changed every 2-3 days and the cells were kept in an incubator at 





2.2.3 hBMSCs isolation on carriers in a small stirred vessel bioreactor (i.e. spinner 
flasks) 
Three different bone marrow-derived hBMSC donor lines were isolated from bone mar-
row aspirates using a bioreactor at University of Aston. 
Small stirred vessel bioreactors (i.e. spinner flasks) were used in this study to evaluate 
the growth of hBMSCs on two different attachment substrates: on Xuri attachment sub-
strates (i.e. waffle macrocarriers; GE Healthcare) and on polystyrene substrates (i.e. 
SoloHill Plastic microcarriers; Pall Life Sciences).  
We received the cell from Aston University, we thawed and expanded the cells in 




2.2.4 PA-hBMSCs pre-conditioning 
PA-hBMSCs and 3D-hBMSCs were cultured until a 70% confluence. Then, the medium 
was discarder and, after 5-washed with PBS 1X, it was replaced with α-MEM-GlutaMax 
medium with only 100U/ml of Penicillin/100μg/ml Streptomycin mixture, without any other 
supplement. Cells were kept in under normoxic (20% O2 and 5% CO2 at 37°C) or hypoxic 
(1% O2 and 5% CO2 at 37°C in a hypoxic incubator, Eppendorf, Hamburg, Germany) 
conditions, for 24 h (for whole secretome analysis) or 72h (for EVs isolation). The PA- 





2.2.5 Analysis of conditioned medium content with cytokine array 
For analysis of whole conditioned medium, after 24h, hBMSCs-CM medium was re-
covered and immediately centrifuged at 300g for 10 min, at 4°C to remove any dead 
cells. Protein content was quantified by Bradford assay and 10μg of proteins were ana-
lyzed with a Proteome Profiler Human XL Cytokine Array Kit (R&D, Minneapolis, Toll 
Free USA, Canada), consist of a nitrocellulose membrane with antibodies spotted in du-
plicate. The membrane was incubated for 1 hour with a blocking solution and then incu-
bated with the samples overnight at 4°C on a rocking platform shaker. The membrane 
was washed to remove unbound material followed by incubation with a cocktail of bioti-
nylated detection antibodies. Streptavidin-HRP and chemiluminescent detection rea-
gents were then applied, and a signal was produced at each capture spot corresponding 
to the amount of protein bound. Images were scanned using the Epson perfection 1260 
scanner and band densities were quantified using the Fiji-ImageJ software. Gene 
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Ontology (GO) was also carried out using DAVID tool (Functional Annotation Bioinfor-




2.2.6 Isolation of Extracellular Vesicles from PA-hBMSCs (h-BMSC-EVs) 
PA-hBMSCs and 3D-hBMSCs were cultured until reaching a confluence of about 60-
70%. In order to have a good extraction yield, cells were never allowed to grow until a 
too high confluence, as this could adversely affect vesicle secretion levels. hBMSCs-EVs 
were obtained after high-speed differential centrifugation of hBMSCs-CM collected from 
about 10 x 106 PA-hBMSCs cultured in serum-free and FBS-containing medium and 
starved for 72 hours under normoxic (FBS-hBMSC-EVsNormo and SF-hBMSC-EVsNormo) 
or hypoxic (FBS-hBMSC-EVsHypo and SF-hBMSC-EVsHypo) conditions. hBMSCs-CM 
were collected in 50ml tubes and cells were trypsinized and counted. The first centrifuge 
was performed at 300g for 10 minutes at 4°C to eliminate dead cells and debris. Once 
the supernatant was recovered, a second centrifuge at 2000g for 20 minutes at 4°C al-
lowed to eliminate the apoptotic bodies from the preparation. As these vesicles are very 
large and their steric encumbrance could trap even the smallest vesicles in the pellet, 
this was precautionally washed with PBS 1x and re-centrifuged at 2000g for 20 minutes 
at 4°C. The supernatant was transferred into ultracentrifuge polyallomer tubes (Beckman 
Coulter, Brea, California, USA), that were placed in appropriate bucket for ultracentri-
fuge. The supernatant was then ultra-centrifuged at 10,000g for 30 minutes at 4°C, to 
pellet microvescicles and finally ultra-centrifuged at 10,000g for 90 minutes at 4°C, to 
pellet the exosomes. The exosome pellet was washed with PBS 1X, previously filtered 
through 0.22μm filter to remove as much as possible the salts of the solution (because 
of nanometric size of exosomes). All the exosome pellets were resuspended together 
into a single clean tube and a last ultracentrifuge was taken at 100,000g for 70 minutes 
at 4°C, to wash the isolated vesicles. At the end of this ultracentrifugation, the superna-
tant was discarder and the pellet was resuspended in 100μl of filtered PBS 1X. 
A Beckman Coulter ultracentrifuge (Beckman Coulter Optima XPN-100 ultracentrifuge; 
Beckman Coulter) was used with swinging bucket rotors type SW28 and SW41Ti. A 
schematic representation of the performed protocol is shown in Fig.13. 
 
Figure 13 Representative scheme of differential ultra-centrifugation protocol 
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2.2.7 Characterization of hBMSC-EVs 
 
Protein quantification by BCA assay 
The concentration of membrane-bound protein on the surface of freshly isolated, intact 
hBMSC-EVs was measured using BiCinchoninic Acid (BCA) assay (Thermo Scientific 
Pierce, Rockford, IL). This method uses a reagent containing bicinconinic acid and is 
based on the reduction of Cu+2 to Cu+1 in presence of proteins in an alkaline medium (the 
biuret reaction) providing colorimetric detection of the cuprous cation (Cu+1). The purple-
colored reaction product of this assay is formed by the chelation of two molecules of BCA 
with one cuprous ion. This water-soluble complex exhibits a strong absorbance at 562nm 
that is nearly linear with increasing protein concentrations over a broad working range 
(20-2000µg/mL). The quantification was performed following manufacturer’s instruc-
tions. The protein content per microliter was normalized to the number of FBS-hBM-
SCsNormo/Hypo, SF-hBMSCsNormo/Hypo and 3D-hBMSCs (1x106). 
 
 
FACS analysis on EVs 
At least six independent preparations of both FBS-hBMSC-EVsNormo/Hypo and SF-
hBMSC-EVsNormo/Hypo were stained with 1μM PE-Cy5-Cell Trace (ThermoFisher Scien-
tific, Waltham, Massachusetts, USA) in combination with the mouse anti-human mono-
clonal antibody (mAb) PE-Cy7-CD63 (Clone: H5C6) (BD Pharmingen, San Jose, CA, 
USA) or the anti-human mAb PE-CD105 (Clone: SN6) (eBioscience, San Diego, CA, 
USA), both diluted 1: 100 in filtered PBS 1X. Cell Trace is a fluorescent dye analog of 
the CFSE (Carboxyfluorescein succinimidyl ester), which is cell permeable and cova-
lently couples to intracellular molecules, staining cells, or vescicles, in this case. Thus, 
we used it to evaluate the vesicular membrane integrity. A set of microsphere suspen-
sions (1.35μm, 0.88μm, 0.45μm and 0.22μm, SpheroTec, Martinsried bei München, Ger-
many) was used as size reference. An unstained sample was acquired to detect the 
sample autofluorescence and set the photomultiplier for all the three used channels. For-
ward and side scatter channels (FSC and SSC) were used on a logarithmic scale visu-
alized in bi-exponential mode. The FSC and SSC photomultipliers were set using back-
ground noise as the lower optical limit, acquiring a sample of sterile PBS tube. The 
threshold, set on the FSC channel, was regulated to reduce the noise progressively, 
allocating dots in low left corner of plot, in order to clearly detect EVs. Samples were run 
on a FACS Aria II (BD Bioscences, San Jose, CA, USA) cytofluorimeter. At least 5x104 
events were analyzed in each instance. 
 
 
Western Blot analysis 
For western blot analysis, the isolated FBS-hBMSC-EVsNormo/Hypo and SF-hBMSC-
EVsNormo/Hypo were resuspended in RIPA buffer (1% NONIDET p-40, 0.1% SDS, 0.1% 
Sodium deoxycholate, protease inhibitor cocktail 1x, in PBS pH 7.5) and protein content 
was quantified by BCA assay. Afterwards, 2-3μg of proteins for each sample were loaded 
on 4%–12% NuPAGE Bis-Tris gel (Life Technologies, Carlsbad, California, USA), elec-
trophoresis was performed at 200V and proteins were blotted on a polyvinylidene fluoride 
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(PVDF) membrane (Millipore, Burlington, Massachusetts, USA) at 350mA (constant A) 
for 2 h and 10 min. After blocking nonspecific sites with 5% non-fat dry milk (Biorad, 
Hercules, California, USA) in Tris Buffered Saline with Tween 20 (TTBS, 20mM Tris pH 
7.5, 500mM NaCl, 0.05% Tween 20) for 1h at RT, blot membrane was incubated over-
night at 4°C with a specific primary antibody (CD9, CD81, or Hsp70, System Biosciences, 
Palo Alto, CA), prepared in 2.5% non-fat dry milk/TTBS at the dilution of 1:1000. The 
following day, washes with TTBS were carried out to remove the excess of antibody and 
the membrane was then incubated with an HRP-anti-rabbit secondary antibody at a di-
lution of 1:20000, for 1h at RT. The positivity was highlighted by providing the substrates 
for the chemioluminescence reaction of HRP (Amersham ECL Western Blotting Detec-
tion Reagent, GE Healthcare, Chicago, Illinois, USA) and impressing a photographic 
sheet by autoradiography (GE Healthcare).   
Images were scanned using the Epson perfection 1260 scanner and band densities 
were quantified using Fiji-ImageJ software. 
 
 
Tunable Resistive Pulse Sensing (TRPS) 
Tunable Resistive Pulse Sensing (TRPS) is a technique that allows high-throughput 
single particle measurements driven through a size-tunable nanopore, one at a time. The 
technique adapts the principle of resistive pulse-sensing, which monitors current flow 
through an aperture, combined with the use of tunable nanopore technology, allowing 
the passage of ionic current and particles to be regulated by adjusting the pore size.360–
362 TRPS provides information about particle concentration, (i.e. number of particles/ml 
for a specified size range), particle size and accurate number based size distribution, 
particle charge and number based charge distribution. Analysis was performed on FBS-
hBMSC-EVsNormo/Hypo, SF-hBMSC-EVsNormo/Hypo and 3D-hBMSC-EVs derived from three 




Analysis of pre-conditioned cells by Scanned Electron Microscopy (SEM)  
PA-hBMSCs were cultured in serum-free and FBS-containing medium on cover 
glasses and then pre-conditioned for EVs production as previously described. Cells were 
washed with PBS 1X and fixed with 2.5% glutaraldehyde for 30 min, then rinsed twice in 
cacodylate buffer solution (Na-cacodylate 1mM). A step of lipid fixation with osmium te-
troxide was performed to better discriminate membrane and vesicles. Cells were there-
fore incubated for 1h with 0.1% OsO4 (Sigma-Aldrich) and washed at least three times 
with cacodylate buffer to remove any trace of osmium. The samples were then dehy-
drated in increasing concentrations of ethanol (50%, 70%, 95%, 100%), transferred to 
an increasing graded series of hexamethyl–disilazane (HMDS), leaved to dry overnight 
under a chemical hood and sputtered-coated with a 7nm chromium-film and 20nm au-








2.2.8 Labeling and Internalization of hBMSC-EVs by hACs  
EVs uptake can be monitored in vitro using a fluorescent dye as PKH67 (Sigma-Al-
drich). The PKH67 is a green fluorescent dye with long aliphatic tails, which can be in-
corporated into lipid regions of the cell membrane. We stained FBS-hBMSC-EVsNormo/Hypo 
and SF-hBMSC-EVsNormo/Hypo with PKH67, according to the manufacture’s protocol. 
Staining was stopped by adding an equal volume of 1% BSA and the EVs were ultra-
centrifuged to remove excess of fluorescence. Stained EVs were given at the concen-
tration of 1μg/ml to hAC plated on glasses for cell culture. After 3 hours, hACs were fixed 
with 4% PFA and marked with Phalloidin to see the cytoskeleton. Nuclei were stained 
with DAPI and glasses were mounted with an aqueous mounting medium. Slides were 
observed at different magnifications and images acquired with the Axiovert 200M micro-




2.2.9 Confocal Microscopy  
The emission signals produced by the fluorochromes, with which the EVs were marked, 
were observed using an inverted microscope equipped with a confocal system high 
speed A1 R MP (Nikon, Minato, Tokyo, Japan). With the conventional microscopy, all 
points of the observed sample are detected simultaneously. In confocal microscopy, the 
image is obtained by the successive scanning of all the points of the observed field. As 
a result, a better spatial resolution is obtained, mainly thanks to the delimitation of the 
focal plane of the image and to a reduced background noise caused by out-of-focus 
signals, accompanied by a notable increase in contrast. The narrow delimitation of the 
focal plane of the image and the possibility of varying this plane allow the successive 
collection of images coming from different planes of the sample, and therefore the ob-
servation of thick preparations by means of their optical sectioning. The final three-di-
mensional image derives from the electronic summation of the single images. 
The confocal system used is equipped with different laser sources: Argon laser emitting 
at 457nm, 476nm, 488nm and 514nm; DPSS laser emitting at 561 nm; two diode lasers 
emitting at 405 nm and at 640nm. 
The sources with λ of 405nm for DAPI, λ of 488nm for FITC and λ of 561nm for TRITC 
were used for the excitation of the three fluorochromes used in the fluorescence assays 
described in the previous paragraph. 
The emission signal is detected by means of single-channel phototubes with filters that 
collect the light signal in different ranges of spectral wavelengths (± 25 nm with respect 
to a central wavelength). 
The emission filters used have the following central wavelength λ: 450 nm, 525 nm and 
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2.2.10 Statistical analysis 
All statistical analysis was performed using one-way ANOVA. Error bars indicate stand-
ard deviation (S.D.). A p-value ≤ 0.05 was considered to be statistically significant. 











2.3.1 Secretome profile of PA-hBMSCs: cells grown in serum-free medium showed 
expression of several cytokines involved in immunomodulation 
The cells were cultured in FBS or serum-free medium, until reaching a confluence of 
about 70%. At this point, the growth medium was replaced with serum-free medium (only 
α-MEM containing 1% Penicillin/Streptomycin), after five washes with sterile PBS 1X, to 
remove any serum or supplement residues. The cells were still cultured under these 
conditions for 24h, parallel in normoxia or hypoxia (1% O2). 
The CM obtained were analyzed by Cytokine Array (R&D). The results showed sig-
nificant differences in the protein content of the conditioned media, with an over-expres-
sion of Chitinase-3-like-1 (CHI3L1) in FBS condition (both nìin normoxia and hypoxia) 
and, on the other side, an over-expression of proteins like angiogenin, pentraxin-3, DKK-
1, thrombospondin-1 and VEGF in serum-free condition (Fig.14). In almost all cases, 
hypoxic treatment did not affect in a very significant way the expression of the various 
cytokines: we noticed that thrombospondin-1, DKK-1 and uPAR decreased in SF-
hBMSC-CMHYPO but they remain much higher than in FBS-hBMSC-CM. 
CHI3L1, a carbohydrate-binding lectin with a preference for chitin, plays a role in reg-
ulation of cell proliferation, adhesion, migration and activation, as well as in tissue re-
modelling,365,366 T-helper cell type 2 (Th2) inflammatory response and IL-13-induced in-
flammation, regulation of allergen sensitization, inflammatory cell apoptosis, dendritic 
cell accumulation and M2 macrophage differentiation.367 In addition, CHI3L1 stimulates 
the production of inflammatory mediators (e.g. CCL2, CXCL2, MMP-9)368 serving as a 
pro-inflammatory biomarker.369 This protein is highly expressed in conditioned media of 
MSCs cultured in vitro in the presence of FBS.370 
We observed that in the media of PA-hBMSCs cultured in serum-free condition there 
are proteins with relevant biological roles which are modulated significantly. This modu-
lation could have important implications from a therapeutic point of view. For instance, 
pentraxin 3 (PTX3) has a role in inflammation and immune response by interacting with 
complement components, thus modulating complement activation. PTX3 regulates com-
plement-driven macrophage-mediated tumor progression, acting as an extrinsic on-
cosuppressor in preclinical models and selected human tumors.371–373 PTX3 play also an 
important role in modulating the cardiovascular system374  and in in bone homeostasis 
and in proper matrix mineralization during fracture repair supporting the maintenance of 
the bone mass possibly by inhibiting fibroblast growth factor 2 (FGF2) and its negative 
impact on bone formation.375  
Finally, we observed high expression of some angiogenic proteins like angiogenin, a 
member of the vertebrate-specific, secreted RNASE superfamily which induces vascu-
larization of normal and malignant tissues376 and VEGF. VEGF is involved in angiogen-
esis, endothelial cell proliferation, survival and fenestration377,378 and in the signaling and 
maintenance of non-endothelial cells, as well as in migration and invasion into the base-
ment membrane, proliferation, survival.379 VEGF has been involved in many other phys-
iological and pathophysiological process including wound healing and bone repair.380 
VEGF has the capacity to promote both osteogenic and angiogenic differentiation381 and 
has been used to enhance bone regeneration due to its promoting effects on angiogen-
esis, cell migration and mineralization.382 
  

































Figure 14 A) Cytokine array assay membrane of PA-hBMSCs-CM (FBS-CM and SF-CM) in normoxic and 
hypoxic conditions. 
B) Quantification of the integrated pixel density for each identified cytokine in the four conditions tested 
with Fiji ImageJ. Error bars represent S.D. (*) P value < 0.05, (**) P value < 0.01, (***) P value < 0.001, (****) 
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2.3.2 Gene Ontology: PA-hBMSCs grown in serum-free medium were more rich in 
cytokines involved in homeostasis, immune response and wound healing 
Gene Ontology (GO) is an enrichment analysis that allows evaluation of the relative 
frequency of ontology terms (i.e. biological functions) in the proteomic profile of interest. 
This allows the identification of ontology terms that occur more frequently in each data 
set when compared with a reference protein dataset. The ontology is divided into three 
areas: Cellular Component (CC, the parts of a cell or its extracellular environment), Mo-
lecular Function (MF, the elementary activities of a gene product at the molecular level, 
such as binder or catalysis), Biological Processes (BP, operations or complexes of mo-
lecular events with a defined beginning and end, relevant to the functioning of integrated 
living units: cells, tissues, organs and organisms). 383,384 
For our analysis in GO we used DAVID (Functional Annotation Bioinformatics Microar-
ray Analysis), focusing on biological processes. For each of the 4 secretomes we iden-
tified several ontologies. Table 1 shows the ontologies related to the proteins involved, 
with the relatives p values and the percentage of representation. FBS-hBMSCs-CM ex-
hibited a panel of cytokines involved mainly in defense and immune response, but, alt-
hough to a lesser extent, also secretion and angiogenesis. SF-hBMSCs-CM showed se-
cretion of proteins influencing immune response (PTX-3, TSP-1), angiogenesis (VEGF, 















































































































































































Table 1 Gene onthology analysis: Biological processes identified by the cytokine clusterization involved 
from three to nine of the selected cytokines. CHI3L1: Chitinase-3-like-1; ANG: Angiogenin; PTX-3: Pentraxin-
3; TSP-1. Thrombospondin-1; DKK-1: Dickkopf WNT Signaling Pathway Inhibitor 1; uPAR: Plasminogen 
Activator, Urokinase; NGAL: Lipocalin-2; OPN: Osteopontin; VEGF: Vascular endothelial growth factor.    
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2.3.3 Hypoxic conditioning of PA-hBMSCs enhances the release of EVs  
The cargo and function of EVs depend on their cells of origin, suggesting that intercel-
lular communication through vesicles is a dynamic system, adapting its message de-
pending on the conditions of the producing cells.354–356,359,385 Changes in oxygen concen-
trations affect many of the distinctive characteristics of stem and progenitor cells.359,386 
On this basis, we evaluated whether hypoxic conditioning of human bone marrow stromal 
cells could influence their EVs secretion. Sub-confluent primary PA-hBMSCs cultured in 
serum-free or FBS-containing medium were maintained for 72 hours in starvation in a 
normoxic or hypoxic environment. After the starvation period, to exclude any negative 
effect on cell viability, we performed a cytofluorimetric assay, using propidium iodide (PI) 
and a FITC-anti-annexin-V antibody, as described in chapter 1 (Par.2.5), so we com-
pared by double staining the percentage of apoptotic cells in the four cell culture condi-
tions, each one in normoxia or hypoxia. We observed that about 60% of FBS-hBMSCs 
resulted viable in both culture conditions (normoxia and hypoxia), but interestingly SF-
hBMSCs showed a stronger resistance to starvation and to hypoxia, exhibiting a share 
of living cells greater than 90% (Fig.15A) 
The CM collected were subjected to differential centrifugations and ultra-centrifuga-
tions, to obtain a pellet containing exosomes, which was then resuspended in filtered 
PBS 1X. BCA assay was performed to evaluate the protein content on the EVs surface. 
Hypoxic preconditioning led to a significant enrichment of proteins on the PA-hBMSC-
EVs surface in both FBS and SF groups (1.11 ± 0.24/106cellsFBS and 1.63 ± 
0.08/106cellsSF) with almost two-fold increase compared to normoxic cells (0.54 ± 
0.12/106cellsFBS and 1.05 ± 0.22/106cellsSF Fig.15B). 
  






Figure 15 A) Representative flow cytometry analysis of control PA-hBMSCs (dead cells) and PA-hBMSCs 
after 72 hours starvation in both normoxic (20%) and hypoxic (1%) culture conditions after staining with 
Annexin V and PI.  
B) BCA assay of the protein concentration of PA-hBMSC-EVsHYPO and hBMSC-EVsNORMO released by 106 
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2.3.4 Hypoxic conditioning of PA-hBMSCs promotes the secretion of smaller ves-
icles 
To detect the right particle concentration and the size distribution, FBS-hBMSC-
EVsNORMO/HYPO and SF-hBMSC-EVsNORMO/HYPO were further analyzed via TRPS using the 
qNano (Izon Science, Oxford, UK). Three measurements were run for each sample, in 
triplicate. We observed a shift in EV size distribution after hypoxic pre-conditioning, in 
both serum-free and FBS cells.  
In normoxic conditions, the ultracentrifuged pellet contained hBMSC-EVs between 100 
and 280nm (SF-hBMSC-EVsNORMO) or 120 and 360nm (FBS-hBMSC-EVsNORMO) 
(Fig.16A), thus including both exosomes and microvesicles. Both FBS-hBMSC-
EVsNORMO and SF-hBMSC-EVsNORMO particle dimension showed average size of 160-
180nm, likely due to clustering effects previously described for other progenitor-derived 
EVs.387  
In hypoxic conditions, instead, the size range of hBMSC-EV was lower, between 80 
and 240nm (Fig.16A), in both FBS and SF cells including also in this case both exosomes 
and microvesicles. Both FBS-hBMSC-EVsHYPO and SF-hBMSC-EVsHYPO particle dimen-
sion showed average size of 120nm.  
The analysis showed a reasonably high number of particles/cell in all the four condi-
tions with almost two-fold increase in SF-derived EVs 303 ± 57.94 particle/cellSF-NORMO 
and 328 ± 23.64 particle/cellSF-HYPO) compared to FBS cultured cells (150 ± 3.77 parti-
cle/cellFBS-NORMO and 195 ± 19.03 particle/cellFBS-HYPO, Fig.16B). Instead, contrary to what 
we have seen with BCA quantification (Fig.9C), we did not observe any significant differ-
ences in particle number between normoxic and hypoxic vesicles in both culture condi-
tions (FBS and SF). Ratio between the number of particles for cell and protein content 
underlined that in both FBS- and SF-hBMSC-EVs, the normoxic pre-conditioning did not 
induce a greater secretion of vesicles, but rather a protein enrichment (Fig.16C). 
SEM analysis also remarked the evidence according to which hypoxic pre-conditioned 
PA-hBMSCs secreted smaller vesicles in both culture conditions (FBS and SF), although 



























Figure 16 A) Tunable Resistive Pulse Sensing (TRPS) analysis measuring size distribution of FBS-hBMSC-
EVs and SF-hBMSC-EVs under normoxia ad hypoxia. 
B) Tunable Resistive Pulse Sensing (TRPS) analysis measuring number of particles within FBS-hBMSC-EVs 
and SF-hBMSC-EVs expressed as particles/cell. Error bars represent S.D. (*) P value < 0.05, (**) P value < 
0.011, Two-way ANOVA. 
C) Ratio particle/protein for single cell. Error bars represent S.D. (*) P value < 0.05, Two-way ANOVA. 
FBS N.: FBS-Normoxia; FBS H.: FBS-Hypoxia; S.F. N.: Serum-free Normoxia; S.F. H.: Serum-free hypoxia 
 
 
~ 69 ~ 
 
 
















Figure 17 Scanning electron microscopy (SEM) analysis of FBS- and SF-hBMSCs after 72 hours of starva-
tion in normoxia (20% O2) and hypoxia (1% O2).  
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2.3.5 PA-hBMSCs secrete CD105+/CD63+ EVs 
In order to characterize isolated EVs, immunoblot and flow cytometry analysis were 
performed. Western blot analysis revealed that both FBS- and SF-hBMSC-EVs express 
the specific vesicular proteins CD81 and CD9, members of the tetraspanin family, prin-
cipally in hypoxia, while the heat shock protein Hsp70 appeared to be present only in 
FBS-hBMSC-EVs under both normoxic and hypoxic conditions, although it is more ex-
pressed under hypoxia (Fig.18C).  
FBS- and SF-hBMSC-EVs were further characterized taking advantage of a multipar-
ametric flow cytometry approach. To separate true events from background noise, EVs 
were defined as events that were included in a dimensional gate which encloses events 
until 0.88μm, which was established according to a well-defined light scatter profile of 
beads with absolute size (Fig.18A). EVs were tagged with the Cell Trace labeling, an 
analogue of CFSE: it is a cytoplasmic fluorescent dye, which acts as marker of vesicular 
integrity. This allowed us to consider only intact membrane structures. We stained Evs 
with either the mesenchymal marker CD105 or the vesicular marker CD63. All types of 
Cell Trace labeled-EVs expressed the CD105 and CD63 antigens, without significant 
differences (Fig.18B). However, the preparation derived from cells grown in serum-free 




Figure 18 A) Flow cytometry strategy adopted to characterize FBS- and SF-hBMSC-EVs. Vesicles were 
stained by the lipophilic dye Cell Trace, the vesicular marker CD63 and the MSC marker CD105. 
B) Histogram showing the percentage of Cell Trace-pos EVs co-expressing CD63 or CD105. Data are 
presented as mean ± SD. 
C) Representative Western blot analysis for EV specific markers (CD81, CD9 and Hsp70) in the four 
experimental groups. 
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2.3.6 Biological effect of hBMSC-EVs on cartilage 
Tissue homeostasis is largely influenced by the immune system. Following tissue dam-
age, it is crucial the immune system activation to eliminate dead or damaged cells. How-
ever, it is equally important that its activation be attenuated after the resolution in order 
to have a right damage recovery. Prolonged immune activation beyond the resolution of 
injury or disease will result in excessive tissue damage or progress to an immune dys-
function disease.135 Therefore, immune homeostasis is a critical component of tissue 
homeostasis. 
In the case of cartilage injury, the rapid upregulation of pro-inflammatory cytokines in-
cluding IL-1, IL-6 and IL-8, and MMP-3 contributes to subsequent matrix degradation 
and joint damage. These pro-inflammatory cytokines and MMPs contribute to the onset 
and development of Osteoarthritis (OA). MSCs have been widely documented to exert 
suppressive and regulatory immunomodulatory effects on both adaptive and innate im-
mune cells in an autologous and allogeneic manner.388–392 MSCs have been intensively 
investigated as a cell-based therapy or in combination with scaffold in a tissue engineer-
ing approach to treat cartilage lesions and OA in both animal and human studies. MSC 
exosomes was recently reported to mediate cartilage repair and regeneration. 
To evaluate the role exerted by EVs in cartilage repair, we began characterizing the 
interactions of EVs with recipient cells. We tested whether human articular chondrocytes 
(hACs) were able to internalize both FBS-hBMSC-EVs and SF-hBMSC-EVs incubating 
them for 3 hours in presence of EVs previously stained with the fluorescent lipophilic 
membrane-diffuse dye PKH67. hACs efficiently internalized EVs within their cytoplasm 
(Fig.19).  
To be sure that EVs were actually internalized and not just stuck on the cell surface, 
we performed a further analysis by confocal microscopy (Fig.20A). The three-dimen-
sional reconstruction demonstrated that hACs really uptook EVs, which were localized 
around the nucleus, at a similar distance in all the conditions (Fig.20B/C). However, cal-
culating the volumetric density (EVs/mm3), it emerged that SF-hBMSC-EVs were mostly 
internalized by hACs respect to FBS-hBMSC-EVs, especially those derived from hypoxic 
cells (Tab.2). 
  





Figure 19 Immunofluorescence analysis of hACs cocultured for 3 hours with normoxic and hypoxic FBS- and 
SF-derived EVs labelled with PKH67 (EVNormo and EVHypo). DAPI (blue), phalloidin (red), PKH67 (green). 
Magnification 63X. Scale bar 20μm. 








Figure 20 A) Confocal microscopy of of hACs cocultured for 3 hours with normoxic and hypoxic FBS- and SF-
derived EVs labelled with PKH67 (EVNormo and EVHypo). DAPI (blue), phalloidin (red), PKH67 (green). 
B) Three-dimensional reconstruction. 
C) Localization of EVs around the nucleus of recipient cells.  
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 Average distance (μm) Volumetric density 
(n°EVs/mm3) 
FBS NORMO EVs 12.7 7*105 
FBS HYPO EVs 13.1 7.5*105 
SF NORMO EVs 12.5 8*105 
SF HYPO EVs 12.7 13.5*105 
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2.3.7 Characterization of 3D-FBS-MSCs-derived EVs   
We received hBMSCs cultured in presence of FBS (3D-FBS) using the Mobius Biore-
actor and agreed Autostem protocols (module 1) from Aston University. The cells were 
thawed and cultured until a confluence of about 70% was reached. At this point, the 
growth medium was replaced with basal medium (α-MEM containing 1% Penicillin / 
Streptomycin) after washing with sterile PBS 1X five times to remove any serum or sup-
plement residues (serum may contain vesicles and it could be a potential source of con-
tamination). To mimic the typical environment established during tissue injury, EVs were 
isolated from the conditioned medium of MSCs harvested under both normoxic and hy-
poxic conditions. The cells were maintained for 72h in starvation. The conditioned media 
obtained were subjected to differential centrifugation and ultra-centrifugation, to obtain a 
pellet containing extracellular vesicles, which was then suspended in filtered PBS (as 
previously described). The preparation of vesicles was first quantified by BCA assay 
(Fig.21A). Protein quantification has allowed us to note bioreactor culture condition 
caused a slight not-significant increase in protein content compared to plastic adherent 
culture. 
To detect the right particle concentration and the size distribution, PA-FBS-EVS and 
3D-FBS-EVs were further analysed via Tunable Resistive Pulse Sensing (TRPS) using 
the qNano (Izon Science, Oxford, UK). Three measurements were run for each sample.  
We observed a difference in EV size distribution, since PA-FBS-EVs contained vesicles 
between 120 and 360 nm (Fig.21B), thus including both exosomes and microvesicles, 
while 3D-FBS-EVs contained also higher vesicles, up to 1 µm, likely due to clustering 
effects previously described for other progenitor-derived EVs.  
The analysis showed a reasonably high number of particles/cell in both conditions with 
almost ten-fold increase in 3DhBMSC-EVs (244.5 ± 7.77 particle/cell) compared to PA-
FBS cultured cells (14.95 ± 0.35 particle/cell, Fig.21C). 
Ratio between the number of particles for cell and protein content underlined that in 
both plastic adherent and 3D FBS cultured cells the protein content is the same 
(Fig.21D). 
 







Figure 21 Characterization of 3D-hBMSC-EVs 
A) Protein quantification by BCA assay. 
B) Tunable Resistive Pulse Sensing (TRPS) analysis measuring size distribution of PA-FBS-EVs and 3D-FBS-
EVs. Error bars represent S.D. (****) P value < 0.0001, t-test. 
C) Ratio particle/protein for single cell. Error bars represent S.D. t-test. 





Regenerative medicine therapies, fueled by advances in stem cell biology and technol-
ogies, seek to direct non-healing injuries towards full restoration of tissue structure and 
subsequent function. Numerous studies have demonstrated that mobilization of endog-
enous stem cells or exogenous administration of a number of stem cell populations to 
injured tissues has resulted in structural regeneration of tissue as well as functional im-
provement.92  
The use of stem cells and particularly Mesenchymal Stem Cells (MSCs) in clinical prac-
tice has increased considerably in the last decade. During this time, the scientific com-
munity has tried to understand their biological mechanisms of action in tissue repair and 
regeneration and unveil their potential in cell therapy and regenerative medicine.393,394 
While the original hypothesis underlying stem cell regenerative therapies was based on 
functional recovery as a consequence of stem cell differentiation,393,395,396 it is now clear 
that other mechanisms of action are at play. A recent paradigm shift has emerged sug-
gesting that the biomolecules synthesized by stem cells may be as important, if not more 
so, than differentiation of the cells in eliciting functional tissue repair. In essence, it has 
been proposed an alternative mechanism called paracrine effect, where MSC secrete 
biologically active molecules that exert beneficial effects on injured tissues164 by promot-
ing angiogenesis and tissue regeneration and inhibiting fibrosis, apoptosis and inflam-
mation.397,398 It has also been shown that they have neurogenic, neuroprotective and 
synaptogenic effects.399,400 Since the survival and differentiation of MSCs at the site of 
the lesion is limited, it is proposed that paracrine signaling is the primary mechanism of 
their therapeutic effects.401 This hypothesis is supported by in vitro and in vivo studies 
showing that many cell types respond to paracrine signaling from MSCs, causing the 
modulation of a large number of cellular responses, such as survival, proliferation, mi-
gration and gene expression.397  
The secretion of bioactive factors is thought to play a critical role in MSC mediated 
paracrine activity. These factors and cytokines may be collected in what has been called 
the conditioned medium (CM), which when transplanted into animal models of different 
diseases have similar effects to those exerted by the cells, increasing the tissue repair 
process in acute myocardial infarction,402,403 wound healing402,403 and as a neuroprotec-
tive agent.404 
In this study, we characterized CM of hBMSCs cultured in a novel serum-free medium, 
to produce cells and cellular products ready for the clinical usage, without animal con-
taminations. We observed that PA-hBMSCs grown in FBS-containing medium appeared 
richer of proteins like Chitinase-3-like-1 (CHI3L1). The glycoprotein CHI3L1, also known 
as YKL-40, is a secreted chitinase family protein that has been implicated in tissue re-
modeling, angiogenesis, and cell survival in both normal and pathological conditions.405–
408 YKL-40 protein is synthesized primarily by classically activated macrophages,409 neu-
trophils,365 ex vivo cultured chondrocytes,410 end stage osteoblasts and primary 
osteocytes,411 osteoblasts treated with TNF-α or IL-1,412 and in lower amounts by other 
tissues of mesenchymal origin. MSCs differentiate into a number of somatic tissues that 
express YKL-40, and changes in YKL-40 expression have been noted in differentiation 
accompanying fetal development in osteogenic and chondrogenic cell lineages.413 It has 
~ 78 ~ 
 
 
been demonstrated also that undifferentiated MSCs contain significant levels of YKL-40 
mRNA but do not synthesize detectable levels of YKL-40 protein. MSCs induced to dif-
ferentiate into chondrocytes and osteocytes soon began to express and secrete YKL-40 
protein, as do ex vivo cultured chondrocytes and primary osteocytes.414 YKL-40 has been 
proposed also as a new marker during adipogenic differentiation of MSCs.415 All these 
findings together led us to suppose that FBS grown PA-hBMSCs could be more commit-
ted than cells cultured in serum-free medium, which appeared indeed more undifferenti-
ated.  
On the other hand, PA-hBMSCs grown in serum-free medium exhibited over-expres-
sion of several bioactive molecules, involved in angiogenesis, tissue homeostasis and 
remodelling, immunomodulation and wound healing. Interestingly, we observed a two-
fold increase of proteins such Pentraxin 3 (PTX3), an essential component of the hu-
moral innate immunity,416 involved in the resistance against microorganisms417 and in-
flammation.418 It is well established that key activators of the inflammatory and reparative 
response after tissue injury, such as proinflammatory cytokines and Toll-like receptors, 
induce PTX3 production in different cell types, including stromal cells.416,419,420 Moreover, 
the secretome of adipose tissue derived MSCs has been showed to contain high levels 
of PTX3 during the early stages of mesengenic differentiation.421 Another study has 
shown that PTX3 plays a protective role in the regulation of tissue repair and remodel-
ling.422 After this finding, using a murine model of skin repair, Capuzzello et al. found that 
Ptx3-deficient (Ptx3-/-) MSCs delayed wound closure and reduced granulation tissue 
formation compared with wt-MSCs, demonstrating an essential role of MSC-derived 
PTX3 in wound repair. 
In our study, also a three-fold increase of Thrombospondin-1 (THBS1) emerged in se-
rum-free cultured cells respect to those grown in FBS-containing medium. The main 
known function of the matricellular protein THBS1 is its anti-angiogenic and anti-inflam-
matory effect in various models, mainly in cancers and cardiac diseases.423 In experi-
mental models of infarction, THBS1 was highly upregulated and THBS1−/− mice exhib-
ited inflammatory infiltrates into the infarcted heart.424 In recent studies it was demon-
strated another crucial role of THBS1, its chondroprotective role. Indeed, using two rat 
models of osteoarthritis, THBS1 was shown to induce regeneration of damaged carti-
lage.425 Similar results were described in other inflammatory models of arthritis: in an 
experimental model of rheumatoid arthritis injection of a peptide-derived from THBS1 
prevented joint infiltration and inflammation and was associated with increased levels of 
connective tissue growth factor (CTGF).426,427 In rheumatoid arthritis patients, altered ex-
pression levels and tissue distribution of THBS1 was observed.428 In a recent study, it 
was shown that coculture of adipose tissue MSCs and chondrocytes had a significant 
induction of THBS1 at mRNA and protein levels. They showed that THBS1 was upregu-
lated at late stages of MSC differentiation toward chondrocytes and that recombinant 
THBS1 (rTHBS1) exerted a pro-chondrogenic effect on MSCs indicating a role of THBS1 
during chondrogenesis. THBS1 exercised also an anti-inflammatory and chondroprotec-
tive function in OA animal model.429 
Our data showed also a slight but anyhow significant increase of factors like Dickkopf-
related protein 1, urokinase-type plasminogen activator receptor and osteopontin. 
Dickkopf-related protein 1 (DKK-1) is a member of the DKK family and it is widely ex-
pressed in many areas including osteoblasts and osteocytes as well as the skin, prostate, 
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placenta and endothelium.430 This protein is seen as a well-characterized antagonist of 
the canonical Wnt signaling. Some studies have shown that activation of the Wnt path-
way is associated with cell proliferation and apoptosis inhibition in tumor cells, and sup-
pression of the pathway is associated with apoptosis and growth inhibition.431 Moreover, 
dysregulation of Wnt signaling has been involved in the pathogenesis of many diseases 
such as cancers, bone disorders, autoimmune diseases, diabetes and Alzheimer dis-
ease.431–436 Therefore, considering DKK-1 as a treatment target for these related dis-
eases would be a beneficial strategy. It has been reported that loss-of-function mutations 
in the Wnt co-receptor, LRP5, can lead to osteoporosis, this report further indicated that 
there was a correlation between the Wnt signaling pathway and bone biology.437,438 The 
Wnt signaling has been shown to participate in bone morphogenesis and homeostasis 
by regulating the process of mesenchymal cell differentiation into mature osteoblasts; 
thus, it might play a crucial role in the anabolic component of joint remodelling observed 
in osteoarthritis.434,439,440  
The multifunctional urokinase receptor (uPAR) is an important mediator of the ana-
phylatoxin C5a/C5a receptor (C5aR) complement cascade controlling C5aR expression, 
C5aR-directed signaling, and related functional effects in kidney mesangial cells and in 
alveolar macrophages in vitro and in vivo.441,442 Our recent findings revealed one further 
novel function of uPAR as a regulator of differentiation and mobilization of bone marrow-
derived MSCs and of their engraftment at the place of injury.443 MSC, which are adult 
stem cells retaining self-renewal capability and unique multilineage potential,444 have 
emerged as the most promising candidate for bone repair. 
Osteopontin (OPN), also known as secreted phosphoprotein 1 (SPP1), is a soluble 
protein that is present in most body fluids. Although OPN may exist intracellularly as a 
regulator of cytoskeleton dynamics and gene expression, most studies have focused on 
the secreted form. Extracellular OPN functions through its interactions with multiple ubiq-
uitously-expressed cell surface receptors, including various integrins (αvβ1, αvβ3, αvβ5, 
α4β1, α8β1, and α9β1) and CD44.445 Binding of OPN to these receptors can elicit a broad 
range of functions, such as cell adhesion, survival, migration and immune regulation.445 
Aberrant expression of OPN has been implicated in numerous physiological and patho-
physiological processes, including bone remodeling,446 responses to stress,447 wound 
repair,448 tumor metastasis449 and autoimmune disorders.450 OPN is abundantly secreted 
by MSCs and can be further up-regulated during the osteogenic differentiation of these 
cells.451 However, little is known about its role in regulating MSC differentiation.  
Our data have therefore shown that PA-hBMSCs grown in serum-free medium could 
have a chondroprotective, anti-inflammatory effect and they could represent a potential 
therapy strategy for diseases such as osteoarthritis and for bone repair, since they se-
creted bioactive molecules involved in these processes, as it also emerged from the gene 
onthology analysis. Over-expressed angiogenic factors were also founded in conditioned 
medium of these cells and this could explain their higher osteogenic potential both in 
vitro and in vivo. 
This study focused on paracrine functionalities of PA-hBMSCs cultured in novel xeno-
free culture system for clinical therapy. Thereafter, we characterized also the extracellu-
lar vesicles (EVs) secreted by these cells in the two different culture conditions. 
EVs represent novel players in various cell communication systems, being involved in 
the regulation of many routes of signaling pathways and intercellular information 
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transfer.95 It is thanks to their vast amount of properties that EVs have been successfully 
applied in different fields, such as tumor biology, immunology and regenerative medi-
cine.452 Stem/progenitor cells and in particular MSCs are active biological components 
of many regenerative medicine therapies.164  
The cargo and the function of the EVs depend on the cell of origin and are the mirror 
of its state of health. The cellular state and the microenvironment influence the secreting 
cell to release vesicles with different contents that can perform different functions and 
determine a response of various types in the recipient cell.385 Hypoxic conditioning can 
change some characteristics of stem cells: growing hMSCs in hypoxia resulted in ap-
proximately 30-fold higher hMSC expansion over 6 weeks without loss of multi-lineage 
differentiation capabilities.386 It has been already demonstrated that hypoxia could influ-
ence also the secretion of EVs in adipose tissue-derived MSCs453 but also in breast can-
cer cells like MCF-7454 and in endothelial cells.455 We proved here that hypoxic pre-con-
ditioning does not affect the number of EVs secreted, but rather the protein content or at 
least the amount of protein associated at the EV-surface. We saw indeed that after hy-
poxia, both FBS- and SF-hBMSC-EVs showed an increase of vesicular markers such as 
CD81 and CD9, while the EVs number remained unchanged. Interestingly, FBS-hBM-
SCs-EVs appeared richer in heat shock protein 70 (HSP70). Exosomal HSP70 has been 
recently shown to have immunomodulatory456,457 and stress moduling activities.458,459 In 
general, these molecular chaperones are usually expressed intracellularly where they 
support the folding and the transport of a great variety of proteins. In contrast, mem-
brane-bound and extracellular-located HSPs act as potent danger signals.460 Several 
pieces of evidence demonstrate that extracellular-located HSPs can be associated to 
extracellular vesicles456,461–463 and this molecule contributed to exosome-induced IFNγ 
production by NK cells.457 In tumoral cells, exosomes overexpressing membrane-bound 
Hsp70 have the capability to induce dendritic cells maturation and stimulate CD4+T and 
CD8+T-cell responses along with the induction of NK cell-mediated immunity in mice464 
and thus they could affect tumor survival and progression.457 
According with some recent studies,465 our data demostrated also that the hypoxic pre-
conditioning increase the percentage of smaller vesicles respect to the normoxic treat-
ment, in both cell culture conditions. This could be also due to a different clusterization 
of the vesicles during the analysis, probably owing to the higher protein concentration: 
exosomes appeared to be very sticky for their hydrophobic features, our hypothesis is 
that the higher protein density of EVsHYPO could decrease this characteristic. 
In line with the chondroprotective biomolecules founded in SF-hBMSCs-CM we ob-
served that EVs derived from serum-free cultured cells were mostly internalized by hu-
man articular chondrocytes, in particular those derived from hypoxic cells. The EV uptake 
mechanisms involve protein interactions that facilitate subsequent endocytosis.261,466–469 
Numerous molecules having this function have been identified, as proteoglycans, lectins, 
tetraspanins. Differences in the surface protein kit could explain the different tendency in 
the uptake of these EVs. Further analysis must be carried out. 
Taken all together, our data suggested that cellular products intended as both condi-
tioned medium derived from PA-hBMSCs cultured in serum-free medium, could show a 
more pronounced osteo-chondro-protective role and they could be therefore employed 
for clinical therapy in cartilage repair. The new culture systems, without animal deriva-
tives, also make the products obtained safe and ready for use in the clinic. 
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Ultimately, we demonstrated also that a culture in three-dimensional condition can 
strongly increase the number of vesicles produced by the cells, according to the litera-
ture.470 
Considering this, it is essential to understand how 3D culture affects the quality of the 
EVs and it is mandatory to re-create in vitro the correct microenvironment that normally 
surrounds the cells in vivo, to be sure that what we are isolating is what is closest to the 
physiological condition. 
  
~ 82 ~ 
 
 
Chapter 3: EVs derived from mesenchymal 





In connective tissues, interactions between cells and the extracellular matrix (ECM) 
govern many aspects of tissue development, homeostasis and cell behaviour, and carti-
lage is an excellent representative of this paradigm.87,89 The cartilaginous tissue is a 
specialized connective tissue, consisting of chondrocytes and a plentiful matrix,471 con-
sisting in turn of a fibrillar component (mainly collagen), and an amorphous component 
(proteoglycans, containing hyaluronic acid), which is responsible for mechanical proper-
ties of this tissue.472,473 
This unique structure, including cells and a vast network of cell regulators, gives carti-
lage a sort of compression rigidity and facilitates the entry of water. Thus, the tissue 
develops a peculiar power to absorb and dissipate tension forces constantly acting on 
the system bone. The high degree of hydration and the movement of water in the matrix 
allow the cartilage matrix to respond to varying pressure loads and contribute to carti-
lage’s weight-bearing capacity. 
Throughout life, cartilage undergoes continuous internal remodelling as the cells re-
place matrix molecules lost through degradation. The structure of the matrix is significant, 
since it acts as a signal transducer for the embedded chondrocytes. Thus, pressure loads 
applied to the cartilage as synovial joints create mechanical, electrical, and chemical 
signals that help to direct the synthetic activity of the chondrocytes.472,474,475 However, as 
the body ages the composition of the matrix changes, and chondrocytes lose their ability 
to respond to these stimuli. In addition to ageing, traumas and diseases of the bones and 
joints, such as osteoarthritis or rheumatoid arthritis, cause disability in millions of people 
worldwide,476 as articular cartilage has limited self-regeneration capacity.472,474,475 The 
lesions on the cartilage can be classified into micro-lesions (lesions that do not reach the 
sub-chondral bone and only superficially affect the tissue) and wounds that reach the 
bone.477–479 The first type of injury makes the area of the damage inaccessible to the 
blood and progenitor cells present in the bone and for this reason there is no self-repair 
mechanisms.477 In the case of wounds that reach the bone, the damage is repaired by 
the mesenchyme stem cells originating from the bone marrow that invade the damaged 
site and replace it with fibrocartilaginous tissue.479 
In addition to these methods that occur naturally in the body, a large number of meth-
ods have been thought to treat articular cartilage.480 We can distinguish surgical ap-
proaches such as bone marrow stimulation techniques (a subchondral bone perforation 
is performed to recall the mesenchymal stem cells from the bone marrow to the damaged 
site),481,482 osteochondral allograft (a cartilage graft transplantation) joint and its underly-
ing sub-chondral bone from a corpse in the patient's damaged site)481, autologous chon-
drocyte transplantation (ACI, the patient undergoes a biopsy and the chondrocytes ob-
tained are implanted in the patient).483–485 No less important is cell therapy based on 
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mesenchymal stem cell transplantation. These cells have a good ability to self-renew 
and a fair chondrogenic potential.486 
Conventionally, the clinical management of an osteochondral injury involves therefore 
the use of mechanical symptomatic measures, in most cases associated to the use of 
analgesics, nonsteroidal anti-inflammatory drugs and/or chondro-protective agents 
(chondroitin sulfate, sulfate glucosamine, hyaluronic acid). Other protective options in-
volve the use of corticoids, HA, PRP, abrasion, micro fracture, radiofrequency and/or 
osteochondral grafts.475,487,488 
It is without doubt that the development of cell-based therapies aimed to repair a dam-
aged cartilage, using either isolated chondrocytes or MSCs as such or in conjunction 
with biological scaffolds has been an area of intensive clinical research in the last years. 
The new approaches provide the use of Tissue Engineering techniques, in which autol-
ogous chondrocytes are seeded on biocompatible scaffolds to produce neo-cartilages.476 
Simultaneously, several attempts have been initiated to further improve chondrogenic 
recovery, exploiting the immunomodulatory properties of mesenchymal stem cells for 
osteoarthritic therapies. 
Osteoarthritis (OA) is the most common form of chronic joint disease affecting 250 
million people worldwide. Over 12% of the aging Western population has been reported 
to suffer from OA, particularly those who are ≥45 years.489,490 It is presently the fastest 
growing major health condition. With an aging population and expanding obesity epi-
demic, OA incidence is anticipated to be the fourth leading cause of disability by the year 
2020.487,488 The pathology of OA is complex involving multiple tissues and processes. It 
is characterized by the degradation of the articular cartilage, degeneration of menisci 
and ligaments, thickening of the subchondral bone, and formation of osteophytes.491 
However, it is often a sequela initiated by articular cartilage injuries caused primarily by 
sports and recreational activities,492 and aging.489,490  
OA is triggered by a local inflammatory response caused by joint instability and accom-
panied by the progressive degeneration of articular cartilage,493 particularly in sites where 
stress exceeds the value that can be sustained by the joint. In a damaged tissue, the 
initial inflammatory response plays a key role triggering tissue repair and homeostasis, 
but can be detrimental in the long term, causing fibrosis.494 However, the exact OA path-
ogenesis remains a subject of debate and research. 
During the OA process, a number of inflammatory mediators have been reported.495 
Interleukin (IL) 1β is considered a main inflammatory mediator resulting in the occurrence 
of OA by damaging articular cartilage via NF-κB pathway activation.495–497 The destruc-
tive effect is also contributed by cyclooxigenase-2 (COX-2), which produces prostaglan-
din E2 (PGE2), resulting in inflammation and pain in OA.498,499 COX-2 expression was 
recently described also in the differentiating growth plate and during chondrocyte differ-
entiation and inflammation.500–504 COX-2 harms the superficial layers of articular carti-
lage, and the NF-κB pathway also plays an important role during the process. 
 Common treatments for OA include nonsteroidal anti-inflammatory drugs, analgesics, 
locally administered corticosteroids. These medications only provide symptomatic relief 
to patients, who will require surgical intervention in the end. Nowadays, efforts have been 
made to reduce the degeneration of articular cartilage, with minimal success.505 
Recently, human multipotent mesenchymal stromal (stem) cells (MSCs) have entered 
clinical trials as a novel, less invasive therapy for cartilage defects and OA.506,507 MSCs 
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are a promising alternative for current therapies as they are more likely to control the 
imbalance between anabolic and catabolic processes in an OA joint, thanks to their im-
munomodulatory and regenerative capacities.508–510 Although the results of this novel 
treatment are promising, the fate of MSCs in vivo and the molecular mechanism under-
lying their beneficial effects in cartilage repair remain unclear. Increasing evidence sug-
gests that the therapeutic efficacy of MSCs depends on paracrine signalling511,512 and 
more recently their therapeutic potential has been attributed to the secretion of bioactive 
factors and extracellular vesicles (EVs).511,512 EVs are secreted by all cell types and 
range in size from 40-100 nm (exosomes) and from 100-1000 nm (microvesicles). Exo-
somes are formed by the invagination of the limiting membrane of multivesicular bodies 
(MVBs), which are part of the cellular endo-lysosomal system. Upon fusion of MVBs with 
the plasma membrane, exosomes are released into the extracellular environment. Mi-
crovesicles bud directly off the plasma membrane.  
EVs released by MSC increasingly appear to play an important role in intercellular 
communication and tissue repair. MSC-EVs have been shown to exert immunomodula-
tory properties in vitro, and to some extent also possess regenerative properties in a 
mouse model of myocardial ischemia/reperfusion injury, a rat skin wound model and a 
rat osteochondral defect model.511,512 
In this study we investigated the regenerative and immunomodulatory potential of con-
ditioned medium and EVs secreted by human bone marrow derived MSC (hBMSCs) in 
chondrocytes from OA patients using an in vitro human cartilage repair model.513 We 
also investigated the activation of the NF-kB pathways and COX-2 expression and their 
downstream products interleukin-6 (IL-6) and IL-8.  
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3.2 Material and Methods 
 
 
3.2.1 Human Bone Marrow Stromal Cells (hBMSC) cultures in plastic adherence 
Plastic Adherent Human Bone Marrow Stromal Cells (PA-hBMSCs) were derived from 
hip bone marrow aspirates of healthy donors, after informed consent. The human sam-
ples were obtained from EU-AutoStem Consortium, after approval by the Clinical Re-
search Ethical Committee at University College Hospital, Galway, Ireland and processed 
at National University of Ireland Galway (NUIG). Briefly, cell nucleated fraction of bone 
marrow aspirate was suspended in α-MEM-Glutamax medium (Gibco, Waltham, MA, 
USA), supplemented with: i) 10% Fetal Bovine Serum (FBS, Gibco), 1ng/ml Fibroblast 
Growth Factor-2 (FGF-2, Peprotech, London, UK) and 100 U/ml of Penicillin/Streptomy-
cin mixture (Euroclone) for standard culture conditions, ii) or with the AutoStem patented 
serum-free supplement and 100 U/ml of Penicillin/Streptomycin mixture. The cells were 
plated at a density of 1x106 cells/cm2. After at least 5 days, only PA-hBMSCs were at-
tached on the plastic, while all the blood cells and other debris were in suspension. Thus, 
the medium was discarded, the cells were washed with Phosphate Buffer Saline 1X 
(PBS) to remove all the refuse and the dishes were refilled with fresh medium. When 
culture dishes were confluent, PA-hBMSC were detached with trypsin-EDTA (Euroclone) 
and cryopreserved for the delivery to our laboratory. After arrival, we thawed the cells 
and 2.5 x 105 cells were plated in 100mm dishes (density of 3000 cells/cm2) and grown 




3.2.2 Isolation and culture of human Arthicular Chondrocytes (hACs) 
Human Articular Chondrocytes (hACs) were obtained from human femoral head biop-
sies of healthy patients, after informed consent. First, the sample was processed with 
the help of a scalpel, in order to withdraw the cartilaginous coating from the joint. The 
pieces obtained were then cut into smaller pieces of about 3mm x 3mm, then they were 
transferred in a 50ml tube, washed with PBS 1x and  resuspended in 1-2mL of a mix of 
enzymatic digestion, consisting of 1mg/mL hyaluronidase (Sigma-Aldrich, Saint Louis, 
Missouri, USA), 400U/mL collagenase I (Wortington Biochemical, Lakewood, NJ ), 
1000U/mL collagenase II (Wortington Biochemical) and 0,25% trypsin (GiBCo) in DMEM 
(Dulbecco’s Modified Essential Medium) High Glucose (EuroClone) w/o FBS. A first di-
gestion of 30 minutes at 37°C was carried out to relax the matrix and it was therefore 
discarded. Various serial digestions were then performed, each one for at least 60 
minutes at 37°C in agitation, to obtain the individual cells. After each digestion, the su-
pernatant was recovered, resuspended in 10mL of DMEM with 10% FBS to block the 
enzymatic activity and centrifuged for 10 minutes at 1200rpm. hAC thus isolated were 
seeded in 1-2 wells of a 6-well plate, in DMEM High Glucose with 10% FBS 2mM L-
Glutamine (EuroClone), 100U/ml Penicillin/Streptomycin, 1mM Na-pyruvate (EuroClone) 
and 10mM HEPES (EuroClone). In each well a liquid hyaluronidase quota of 8U/mL was 
also added, in order to break up any aggregates of cells still present in the suspension. 
The medium was changed every 2-3 days and the cells were kept in an incubator at 
~ 86 ~ 
 
 





3.2.3 PA-hBMSCs pre-conditioning 
PA-hBMSCs were cultured until a 70% confluence. Then, the medium was discarder 
and, after 5-time washing with PBS 1x, it was replaced with α-MEM-Glutamax medium 
with only 100 U/ml of Penicillin/Streptomycin mixture, without any other supplement. 
Cells were keeped in culture for 24 h (for whole secretome production) or 72h (for EVs 





3.2.4 Isolation of Extracellular Vesicles from PA-hBMSCs (h-BMSC-EVs) 
PA-hBMSCs were cultured until reaching a confluence of about 60-70%. In order to 
have a good extraction yield, cells were never grown until a too high confluence, as this 
could adversely affect vesicle secretion levels. hBMSCs-EVs were obtained after high-
speed differential centrifugation of hBMSCs-CM collected from ca. 10 x 106 PA-hBMSCs 
cultured in serum-free and FBS-containing medium and starved for 72 hours. hBMSCs-
CM were collected in 50ml tubes and cells were trypsinized and counted. The first cen-
trifuge was performed at 300rcf for 10 minutes at 4°C to eliminate dead cells and debris. 
Once the supernatant was recovered, a second centrifuge at 2000rcf for 20 minutes at 
4°C allowed to eliminate the apoptotic bodies from the preparation. As these vesicles are 
very large and their steric encumbrance could trap even the smallest vesicles in the pel-
let, this was precautionally washed with PBS 1x and re-centrifuged at 2000rcf for 20 
minutes. The supernatant was transferred into ultracentrifuge polyallomer tubes, in turn 
placed in appropriate bucket for ultracentrifuge. The supernatant was then ultra-centri-
fuged at 10.000rcf for 30 minutes at 4°C, to pellet microvescicles and finally ultra-centri-
fuged at 100.000rcf for 90 minutes at 4°C, to pellet the exosomes. The exosome pellet 
was washed with PBS 1x, previously filtered with 0.22μm filter to remove as much as 
possible the salts of solution (because of nanometric size of exosomes). The resuspen-
sions were combined into a single clean tube and a last ultracentrifuge was taken at 
100,000rcf for 70 minutes, to wash the isolated vesicles. At the end of this ultracentrifuge, 
the tube was emptied of the supernatant and drained. The pellet was resuspended in 
100μl of filtered PBS 1x. 
A Beckman Coulter ultracentrifuge (Beckman Coulter Optima XPN-100 ultracentrifuge; 
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3.2.5 Labeling and Internalization of hBMSC-EVs by OA hACs  
EVs uptake was monitored in vitro using a fluorescent dye as PKH67 (Sigma-Aldrich). 
The PKH67 is a green fluorescent dye with long aliphatic tails, which can be incorporated 
into lipid regions of the cell membrane. We stained FBS-hBMSC-EVs and SF-hBMSC-
EVs with PKH67, according to the manufacture’s protocol. Staining was stopped by add-
ing an equal volume of 1% BSA and the EVs were ultra-centrifuged to remove excess of 
fluorescence. Chondrocytes were previously treated with 200U/ml IL-1α (Peprotech, 
London,UK) for 16 hours to mimic an inflammatory condition in vitro and thus obtain OA-
hACs. After this pre-treatment stained EVs were given to OA-hACs plated on glasses for 
cell culture. After 3 hours, hACs were fixed with 4% PFA and marked with Phalloidin to 
see the cytoskeleton. Nuclei were stained with DAPI and glasses were mounted with an 
aqueous mounting. Slides were observed at different magnifications and images ac-




3.2.6 Western blot 
Confluent HACs (at passage 1) were treated for 16 or 48 hours with a medium supple-
mented with 200U/ml IL-1a, 200U/ml IL-1a FBS-hBMSC-CM at three different concen-
trations 1, 10,100μg/ml, 200U/ml IL-1a SF-hBMSC-CM at three different concentrations 
1, 10,100μg/ml or without any supplement. Media were then removed, and cells exten-
sively washed with PBS before being transferred to a serum-free medium (no FBS) for 
24 h. HAC-Conditioned serum-free culture media were collected and quantified by Brad-
ford assay. 200μl of each sample were precipitated adding 10%TCA (Trichloroacetic 
acid) and centrifuging samples for 20 minutes at 14,000rpm. The pellet of proteins was 
resuspended in Sample Buffer and loaded on 4%–12% NuPAGE Bis-Tris gel (Life-Tech, 
Carlsbad, California, USA), electrophoresis and blot were performed according to a pro-
tocol previously optimized in our laboratory. Blot membranes were incubated with spe-
cific primary antibodies against IL-6 and IL-8 (1:200, Santa Cruz Biotechnology) (n = 3). 
Western blot analysis for COX-2 on cell lysates was also performed. To this purpose, 
cells were scraped in 30μl of RIPA buffer and quantified by Bradford assay. 10μg of 
proteins for each sample were loaded on 4%–12% NuPAGE Bis-Tris gel and electropho-
resis and blot were performed. Blot membranes were incubated with specific primary 
antibodies against COX-2 (1:500, Abcam, Cambridge, UK) (n = 3).  
To investigate the effect of hBMSC-EVs, confluent HACs (at passage 1) were pre-
treated for 3 hours with with 1μg/ml FBS-hBMSC-EVs or 1μg/ml SF-hBMSC-EVs in 6-
well plates. After 3 hours, 200U/ml IL-1a was added to each well. A negative control 
without any supplement and a positive control treated only with 200U/ml IL-1a were also 
carried out. Cells were lived in culture for other 24 hours. Media were then removed, and 
cells extensively washed with PBS before being transferred to a serum-free medium (no 
FBS) for 24 h. cells were scraped in 30μl of RIPA buffer and quantified by Bradford assay. 
10μg of proteins for each sample were loaded on 4%–12% NuPAGE Bis-Tris gel and 
electrophoresis and blot were performed. Blot membranes were incubated with specific 
primary antibodies against COX-2 (1:500, Abcam, Cambridge, UK) and LECT-1 (1:1000, 
LS Bio, Seattle, Washington, Stati Uniti) (n = 3).  
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Images were scanned using the Epson perfection 1260 scanner and band densities 
were quantified using the Fiji-ImageJ software. Different pixel mean densities were ana-




3.2.7 NF-kB nuclear translocation 
Chondrocytes were cultured in 24-well plates on glass coverslips. They were treated 
for 4 or 40 hours with a medium supplemented with 200U/ml IL-1a, 200U/ml IL-1a FBS-
hBMSC-CM at three different concentrations 1, 10,100μg/ml, 200U/ml IL-1a SF-hBMSC-
CM at three different concentrations 1, 10,100μg/ml or without any supplement. Cells 
were fixed in 3,7% paraformaldehyde in PBS (pH 7.6) containing 2% sucrose for 10 
minutes. After washing in PBS, cells were permeabilized with a solution (20mM HEPES, 
300mM sucrose, 50mM sodium chloride, 3mM magnesium chloride, and 0.5% Triton X-
100) for 10 minutes at 4°C. Nonspecific binding was prevented by incubation with pure 
goat serum for 30min at 4°C. Slides were incubated with a rabbit anti-NFκB p65 antibody 
(1:100; Cell Signaling) overnight at 4°C. After rinsing in PBS, an anti-rabbit fluorescence-
labeled antibody Alexafluor-488 (Life Tech) was added for 30min. Cells were marked 
with Phalloidin to see the cytoskeleton. Nuclei were stained with DAPI and glasses were 
mounted with an aqueous mounting. Slides were observed at different magnifications 




3.2.8 Statistical analysis 
All statistical analysis was performed using one-way ANOVA. Error bars indicate stand-
ard deviation (S.D.). A p-value 0.05 was considered to be statistically significant. 
GraphPad software was used as work program. 
 
  





3.3.1 Osteoarthritic chondrocytes are more prone to internalize hBMSC-derived 
EVs  
It has been shown that mesenchymal stem cell exosomes often have an immunosup-
pressive and anti-inflammatory role. We therefore wondered if our exosomes could have 
effects in counteracting osteoarthritic processes (characterized by inflammatory pro-
cesses) in the field of cartilaginous and bone lesions. We hypothesized that BMMSC-
EVs interact with chondrocytes from osteoarthritic patients to modulate cartilage regen-
eration. 
Therefore, we started from primary cultures of human articular chondrocytes (HACs), 
we induced an inflammatory process, using a dose of 200U / ml of IL-1α and we gave 
exosomes, previously marked with a fluorescent dye, to the cells, at a concentration of 
1μg / ml. After three hours, the cells were fixed with 3.7% PFA, treated with DAPI and 
mounted on a slide for fluorescence microscopy observation.  
hBMSC-EVs not only interacted but were taken up by OA chondrocytes after as short 
as 3 hours of incubation (Fig.22A) 
A quantitative analysis was also performed counting the percentage of positive cells 
per ROI (Region of Interest, Fig.22B). FBS- and SF-hBMSC-EVs showed a similar inter-
nalization efficiency both in normal (30.44 ± 0.56% and 39.95 ± 2.12% respectively) and 
inflammatory (53.06 ± 6.46% and 54.87 ± 7.1%). Both type of EVs are internalized with 
a higher efficiency following treatment with interleukin. Although the counts did not find 
significant differences, the share of SF-hBMSC-EVs for each cell in OA-hAC appeared 
much higher and the signal is located close to the nucleus, suggesting a localization in 
the endoplasmic reticulum. Further experiments will be conducted on the subject for clar-
ification regarding the fate of the EVs after the endocytosis. 
These data indicate that bone marrow MSC secrete EVs that interact and are rapidly 










Figure 22 A) PKH67+ hBMSC-EVs uptake by hACs and OA-hACs.  
B) Quantification of PKH67 positive cells Error bars represent mean ± S.D. (*) P < 0.05, two-way ANOVA. 
A 
B 
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3.3.2 hBMSC-CM inhibited IL-1α-induced pro-inflammatory cytokine secretion and 
COX-2 expression in osteoarthritic chondrocytes 
In a damaged tissue, the initial inflammatory response plays a key role triggering tissue 
repair and homeostasis, because it serves to recall progenitor cells to start the regener-
ation. If this inflammatory response retains for a long time, it can be detrimental, causing 
chronic inflammation and fibrosis. 
We evaluated the effect of hBMSC-CM on protein secretion of the proinflammatory 
cytokines IL-6 and IL-8 in hACs cultured under normal and inflammatory conditions 
(Fig.23A/B). Confluent chondrocytes (at P1) were treated for 16 and 48 hours with the 
serum-free medium supplemented with 200U/ml IL-1a, 200U/ml IL-1a FBS-hBMSC-CM 
at three different concentrations 1, 10,100μg/ml, 200U/ml IL-1a SF-hBMSC-CM at three 
different concentrations 1, 10,100μg/ml or without any supplement. At the end of the 
incubation time, culture media were removed and replaced with serum-free media (no 
supplements). After additional 24 h of incubation, media were collected, and secreted 
proteins were detected by Western blot and quantified.  
In a parallel experiment, gene expression levels were measured and quantified, in ly-
sates of the cells after 16 and 48 hours of the different treatments (Fig.23C). The secre-
tion of both IL-6 and IL-8 increased after 16 hours when the chondrocytes culture me-
dium was supplemented with IL-1α, as compared to controls (Fig.23A/B). Interestingly, 
when the medium was supplemented with FBS-hBMSC-CM plus IL-1α, the IL-6 and IL-
8 levels were significantly higher than with IL-1α alone, in a concentration-dependent 
manner. An increase of IL-6 and IL-8 was observed also after the treatment with 1μg/ml 
SF-hBMSC-CM plus IL-1α, while with the treatment at 10 and 100μg/ml the cytokines 
secretion decreased considerably.  
After 48 hours of treatment, while with FBS-hBMSC-CM plus IL-1α and IL-1α the IL-6 
and IL-8 remained elevated, indicating the persistence of an inflammatory state, with SF-
hBMSC-CM these levels were drastically reduced. In particular, we saw a concentration-
dependent decrease of IL-8 levels. 
The effect of conditioned media on COX-2 expression was also examined by western 
blot. The levels of COX-2 were increased in cells treated with IL-1α, as compared to 
controls (Fig.23C), both after 16 and 48 hours. The simultaneous treatment with SF-
hBMSC-CM induced an increase of COX-2 in the first hours, but it was then inhibited 
after 48 hours, indicating the establishment of an acute pro-resolving inflammation and 
suggesting a role of these CM in inflammation resolution. The same result was not found 
with FBS-hBMSC-CM treatment. 
 
  








IL-1α                        -         +        +       +         +        +       +         + 
FBS-CM (ug/ml)     -         -        1      10     100      -        -          - 
SF-CM (ug/ml)       -         -         -        -         -         1      10     100 
IL-1α                        -       +       +       +        +         +        +         + 
FBS-CM (ug/ml)    -       -        1      10    100        -        -          - 
SF-CM (ug/ml)       -       -        -         -       -          1       10     100  
IL-1α                        -         +       +       +       +       +       +       + 
FBS-CM (ug/ml)     -         -       1      10    100     -        -        - 
SF-CM (ug/ml)       -         -        -         -        -       1      10    100 
IL-1α                        -       +       +       +         +          +        +        + 
FBS-CM (ug/ml)     -       -       1      10     100        -          -        - 
SF-CM (ug/ml)       -       -       -         -          -          1       10    100 
IL-1α                        -          +         +        +        +        +         +         + 
FBS-CM (ug/ml)     -          -          1       10     100      -         -          - 
SF-CM (ug/ml)       -           -          -         -         -        1        10      100 
IL-1α                        -        +       +        +         +        +          +        + 
FBS-CM (ug/ml)     -        -       1       10      100      -          -         - 





COX-2 16h COX-2 48h 
Figure 23 Western blot on conditioned medium derived by hACs treated with IL-1α + FBS- or SF.derived CM, for 
protreins IL6 (A), IL-8 (B), COX2 (C). Error bars represent S.D. (*) p value < 0.05, (**) p value < 0.01, (***) p value< 
0.001, (****) p value < 0.0001, ANOVA. 
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3.3.3 hBMSC-CM inhibited IL-1α-induced pro-inflammatory NFκB signaling in os-
teoarthritic chondrocytes 
NF-κB signaling is the major signaling pathway activated by TNF-alpha in OA chondro-
cytes.514,515 
To understand whether the anti-inflammatory effect of hBMSC-CM could be mediated 
through the regulation of NFκB activity, we treated hACs for 4 and 40 hours with the 
serum-free medium supplemented with 200U/ml IL-1a, 200U/ml IL-1a FBS-hBMSC-CM 
at three different concentrations 1, 10,100μg/ml, 200U/ml IL-1a SF-hBMSC-CM at three 
different concentrations 1, 10,100μg/ml or without any supplement. We analyzed the 
subcellular localization of the p65 subunit of NF-κB. As expected, treatment of chondro-
cytes with IL-1α induced translocation of p65 from cytoplasm to nucleus suggesting NF-
κB activation, which could be abrogated by hBMSC-CM from both FBS and serum-free 
cultured hBMSCs.  
Interestingly, after a 4-h stimulation with IL-1α and IL-1α + hBMSC-CM, we detected 
the upregulation of NF-kB as compared to untreated. After 40 h, the activity of NF-kB in 
the presence of hBMSC-CM + IL-1α was subverted with a significant reduction as com-
pared to IL-1α alone (Fig.24) 
These data suggested that both FBS- and SF-hBMSC-CM could potentially affect the 
inflammatory status of osteoarthritic condition, but SF-hBMSC-CM appeared to be much 
more effective. 








Figure 24 Chondrocytes from three patients were treated with hBMSC-CM from one allogeneic hBMSC 
donor and with 200U/ml IL-1α for 4 and 40 hours.  
(A) hBMSC-CM inhibited IL-1α-induced nuclear translocation of p65 subunit of NF-κB. Nuclear trans-
location of p65 subunit of NFκB was assessed by immunofluorescence analysis. Representative images 
of three independent experiments are shown.  
(B) Quantification of data presented in A. Data from three independent experiments are shown as 
mean ± SD. (***) P value < 0.001, (****) P value < 0.0001, two-way ANOVA. 
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3.3.4 hBMSC-EVs exhibited a chondro-protective role 
To investigate the effect of hBMSC-EVs, confluent HACs were pre-treated for 3 hours 
with 1μg/ml FBS-hBMSC-EVs or 1μg/ml SF-hBMSC-EVs in 6-well plates. After 3 hours, 
200U/ml IL-1a was added to each well. A negative control without any supplement and 
a positive control treated only with 200U/ml IL-1a were also carried out. Cells were lived 
in culture for other 24 hours. Media were then removed, and cells extensively washed 
with PBS before being transferred to a serum-free medium (no FBS) for 24 hours. 
We analyzed the levels of COX-2: the simultaneous treatment with FBS-hBMSC-EVs 
induced a decrease of COX-2 and this effect was stronger after the treatment with SF-
hBMSC-EVs (Fig.25) 
We investigated also the effect of LECT-1 expression. Chondromodulin-1 (ChM-1, or 
LECT-1) is a marker of hyaline cartilage and it has the following biological functions: i) 
stimulation of the synthesis of DNA and extracellular matrix and promotion of the rapid 
growth of chondrocytes and cartilage.516,517 ii) Inhibition of angiogenesis, which can in-
hibit vascular invasion into cartilage and thus inhibit endochondral bone development 
and bone ossification.517,518 
We saw here that the pre- treatment with both FBS- and SF-hBMSC-EVs allowed a 
recovery of LECT-1 levels, which was inhibited with the IL-1α inflammation. 
Taken all together, these data suggested that hBMSC-EVs could have a chondro-pro-








Figure 25 Response of human articular chondrocytes to the hBMSC-EVs treatment in an inflammatory 
microenvironment. Identification of proteins in chondrocyte was performed after the cell different treatments. 
Western blot analysis of COX-2 and LECT-1 was performed and the corresponding band intensity was de-
termined by densitometric analysis (n = 3). 




In joint, under physiological conditions, chondrocytes, the extracellular matrix, and cell 
secretome (i.e., the whole joint microenvironment) are responsible for the maintenance 
of tissue homeostasis. However, when a lesion occurs, profound changes perturb the 
microenvironment. The proinflammatory cytokine IL-1α produced in the inflamed joints 
by activated synovial cells and infiltrating macrophages is one of the most potent cata-
bolic factors in knee diseases.511,512 
This molecule is responsible for the induction of several mediators of cartilage degen-
eration such as IL-6 and IL-8. In this condition, the cells near to the site of the injury are 
not able to organize an acceptable regenerative response and, as a consequence, the 
cartilage normal structure and composition are not restored. 
Osteoarthritis is one of the most prevalent joint diseases and a major public health 
problem. It is characterized by progressive articular cartilage destruction and synovi-
tis.511,512 Current therapies attempt to relieve the symptoms, but they cannot stop or re-
verse the ongoing cartilage degeneration.511,512 The ideal treatment aiming for an optimal 
OA joint repair should promote regenerative properties of chondrocytes and fight de-
structive effects of inflammation.  
A wide range of evidence indicates that paracrine effects of MSC are a central mech-
anism of cell therapy promoting tissue regeneration.511,512 
We compared the effects of hBMSC-CM and EVs on hACs maintained under physio-
logical and inflammatory conditions (i.e., in the presence of IL-1α). The addition of CM 
derived from hBMSCs cultured in FBS-containing medium itself did not modify the se-
cretion profile of the proinflammatory cytokines IL-6 and IL-8 but caused an increased 
secretion of these factors enforcing the IL-1α activity. On the other hand, the treatment 
with CM derived from hBMSCs cultured in our novel well-defined xeno-free culture me-
dium downregulated the pro-inflammatory cytokines IL-6 and IL-8, after an initial in-
crease. 
This may have implications for the control of altered chondrocyte metabolism. Interest-
ingly, IL-6 has been involved in OA pathophysiology519 and increased circulating levels 
of IL-6 have been associated to radiographic knee OA.520 
Elevated levels of TNF-α, IL-1 and IL-6 have been found in the synovial fluid, synovial 
membrane, subchondral bone and cartilage of OA patients, confirming their important 
roles in OA pathogenesis. Moreover, TNF-α, IL-1 and IL-6 can induce the production of 
other cytokines, matrix metalloproteinases (MMPs) and prostaglandins and inhibit the 
synthesis of proteoglycans and type II collagen; thus, they play a pivotal role in cartilage 
matrix degradation and bone resorption in OA. Activated chondrocytes also produce 
MMP-1, MMP-3, MMP-13, and aggrecanase 1 and 2 (ADAMTS-4, ADAMTS-5). In addi-
tion, IL-1, TNF-α and IL-6 may cause OA indirectly by regulating release of adiponectin 
and leptin from adipocytes.521 
Osteoblasts stimulated by IL-1β, TNF-α, and IL-6 become a source of IL-6 and secrete 
MMPs, thus adversely affecting the cartilage located nearby.522 IL-6 stimulates normal 
cartilage and synovial cells to produce large amounts of prostaglandin E and increases 
collagenase levels. Collagenase degrades collagen, promotes cartilage absorption, and 
activates MMPs to digest matrix proteins, resulting in loss of matrix water. This abnormal 
phenomenon causes deterioration of the microenvironment for chondrocyte survival, 
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making it impossible for the cells to obtain sufficient nutrients, thereby causing self-im-
pairment of function; this process can form a vicious circle, ultimately causing articular 
cartilage degradation.523,524 
IL-6 stimulates osteoclast differentiation and growth, promotes osteoclast formation, 
and increases osteoclast activity, thereby acting in synergy with IL-1β and TNF-α to dam-
age articular cartilage.522,525 
In OA chondrocytes, canonical NF-κB signaling mediates the induction of inflammatory 
mediators and catabolic mechanisms as well as cellular differentiation changes which 
favour the onset and perpetuation of disease.523,524 A reduction in the activation of this 
transcription factor by CM and EV could contribute to the downregulation of IL-6, IL-8 
COX-2, and MMPs.526  
The inhibition of NF-kB has been recently reported as actuated by the hBMSC-EVs.330 
Moreover, in primary human osteoarthritic chondrocytes, it was observed that EVs inhib-
ited the translocation of NF-kB to the nucleus. Here, we extend these observations and 
report that our novel culture system provides cells able to secrete bioactive factors in 
conditioned medium with the capability to restore the homeostatic status of osteoarthritic 
cartilage. In primary hACs, hBMSC-CM, in combination with IL-1α, drives the initial tran-
sient activation of NF-kB (4-h treatment) with consequent upregulation of IL-6 and IL-8, 
whereas a longer time of treatment (40 h) causes a reduction of the NFkB activity. Based 
on these data, we suggest that the activation and the subsequent inhibition of NF-kB is 
involved in the inflammation response and resolution controlled by CM. 
We found that also COX-2, an enzyme activated during the acute-phase response, 
was significantly reduced. Several studies demonstrated that in the skeletal systems, 
COX-2 is expressed during fracture callus formation, being its function essential for bone 
healing.527 In cartilage, the activation of COX-2 was described not only in the differenti-
ated growth plate, but also during inflammation.528–530 Ulivi et al. showed that in a chon-
drocyte cell line, COX-2 was expressed via p38/NF-kB activation and nuclear transloca-
tion during both differentiation and inflammatory response.500 In this context, our obser-
vation that hBMSC-CM in the presence of IL-1α was able to reduce not only NF-kB, but 
also COX-2 expression indicates to an early attempt to obtain the resolution of the in-
flammation process. We therefore propose that in cartilage, the hBMSC conditioned me-
dia initially enhance the inflammatory response, thus promoting a transient inflammation 
of the HACs, but trigger a cascade of events leading to inflammation resolution. 
However, our data also demonstrate that both FBS- and SF-BMMSC-EVs from two 
independent hBMSC-EVs donors inhibited IL-1α-induced expression of COX2, indicating 
their significant anti-inflammatory potential in cartilage cells.  
Although, BMMSC-EVs stimulated an almost 2-fold reduction in COX2 expression, 
their relative contribution to the effect of the total MSC secretome was smaller compare 
to their strong regenerative properties. The other secretory factors present in hBMSC-
CM seem to play, next to EVs, an important role in hBMSC immunomodulatory effects 
on OA chondrocytes.  
However, analysis of hBMSC-EVs’ impact on immune cells present in synovial fluid 
and immune cells penetrating joint synovial tissue of OA patients, such as macrophages, 
should give a more complete picture of hBMSC-EVs anti-inflammatory properties. 
Last but not least, pre-treatment with both FBS- and SF-hBMSC-EVs allowed a recov-
ery of LECT-1 levels, which was inhibited with the IL-1α inflammation. LECT-1 promotes 
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chondrocyte growth and inhibits angiogenesis. This gene is expressed in the avascular 
zone of prehypertrophic cartilage, and its expression decreases during chondrocyte hy-
pertrophy and vascular invasion. The mature protein likely plays a role in endochondral 
bone development by permitting cartilaginous anlagen to be vascularized and replaced 
by bone. It may also be involved in the broad control of tissue vascularization during 
development. 
  





Taken together, the data presented here demonstrate for the first time that hBMSC-
CM and EVs have both regenerative and immunoregulatory properties in human OA 
cartilage. We demonstrated with our work that we developed a novel serum-free culture 
system which allows to isolate hBMSCs with high chondro-protective role and the cellular 
product obtained are safe at clinical grade and devoid of animal derivatives. 
The dual potential of hBMSC-CM/EVs makes them a promising candidate for an opti-
mal therapy for OA, which should promote cartilage repair and inhibit ongoing cartilage 
degradation. Additionally, hBMSC-CM/EVs-based therapy seems to carry less safety 
risk, since EVs, in contrast to cells, cannot replicate or become transformed. Therefore, 
hBMSC-EVs could be administered at earlier stages of OA to improve joint homeostasis 
and prevent OA from further development. This would potentially lower or delay the ne-
cessity of surgery for these patients. In cases of advanced OA, BMMSC-EVs could be 
used to improve the joint condition and might need to be supplemented with other treat-
ment approaches such as cell-transplantations or joint distraction, as there is hardly any 
cartilage left in late-stage OA joints. 
However, BMMSC-EV therapy has little precedence, thus its ethical status needs to be 
clearly defined before it can be introduced to clinics. This may require more in-depth 
characterization of BMMSC-EVs regarding their RNA and protein content. 
In vivo studies are also underway to evaluate the regenerative potential of these cells 
and their cellular products in a bone damage system in diabetic mice (the diabetic mouse 
has a lower ability to self-regenerate a critical bone defect). 
Our culture system showed to be suitable to isolated hBMSCs and cellular product 
ready-to-use for clinical therapy, as it allows to isolate and maintain in culture a large 
quantity of cells, in a short time, in a culture system devoid of animal derivatives and 
contaminations due to manipulation, thus obtaining a safe high clinical grade product, 
compatible with GMP rules. 
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